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Göteborg, Sweden 
ABSTRACT: Chronic inflammation has been suggested to be linked to cancers. 
Inflammatory infiltrates are often found in and around foci of prostatic atrophy. These foci, 
called proliferative inflammatory atrophy (PIA), are proposed as precursors of prostate cancer 
(PCa) or prostatic intraepithelial neoplasia (PIN). Up-regulated cyclooxygenase-2 (COX-2) 
may play a role in influencing cell proliferation, differentiation, apoptosis, and angiogenesis. 
In the present studies, we found that COX-2 was overexpressed in the PIA lesions. Epithelium 
in these PIA lesions had high proliferation index and increased level of anti-apoptosis protein 
Bcl-2. The association between COX-2 and the focal chronic inflammation, dominant T-
lymphocytes and macrophages infiltration, was clearly shown. This study suggests that 
chronic inflammation and the related oxidative stress might play crucial roles in inducing 
COX-2 overexpression, which could be involved in the pathogenesis of prostate disorders.  
Transcription factor CCAAT/enhancer-binding protein  (C/EBP) plays a major role during 
the initial stage of COX-2 transcription. In the present study we report a novel finding that 
C/EBP was overexpressed in PIA lesions and in relation to COX-2. The data also 
demonstrates that chronic inflammation appeared to play a role in inducing C/EBP
expression in atrophic prostate epithelial cells.  
Using a similar technique, we investigated COX-2 expression in human PCa tissue and found 
that COX-2 expression correlated with Gleason score. The focal chronic inflammation in the 
cancer areas seems to induce COX-2 expression, since the COX-2 expression was 
significantly related to inflammation density. This study provides the first evidence of a direct 
link between COX-2 and angiogenesis in PCa tissues.  
Morphological transition from PIA to HGPIN and PCa was found in radical prostatectomy 
specimens, although it was not very common. Atrophic epithelial cells are easy to recognize 
and clearly delineated by CK5 and GSTP1 immunostaining. One striking finding of this study 
is that clusters of cells that show nuclear atypia were found in some PIA lesions. Such focal 
atypical epithelial cells fulfil the criteria for HGPIN and expressed both CK5 and GSTP1. 
This study suggests that PIA lesions may develop into HGPIN and prostate cancer directly or 
via some intermediate process. 
Key words: prostate, carcinogenesis, chronic inflammation, atrophy, morphology, 
immunohistochemistry 
ISBN: 978-91-628-7348-6 
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PG prostaglandin 
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TNF tumour necrosis factor alpha 
VEGF vascular endothelial growth factor 
9BACKGROUND 
Prostate Gland 
Anatomy 
The prostate is an accessory genital gland with the size and shape of a chestnut. The gland is 
located in the pelvis, inferior to the bladder, where it surrounds the prostatic part of the 
urethra. It consists of 30 to 50 tubuloalveolar glands arranged in three concentric layers: an 
inner mucosal layer, an intermediate submucosal layer, and a peripheral layer containing the 
main prostatic glands 1-3. The glands of the mucosal layer secrete directly into the urethra; the 
other two layers have ducts that open into the prostatic sinuses, located on either side of the 
urethral crest on the posterior wall of the urethra 3.  
The adult prostate gland can be divided into four anatomical zones 4.
• The peripheral zone (PZ): The PZ is located predominantly in the posterior and lateral aspects of 
the gland, extends to the apex variably and anteriorly, and surrounds the central zone towards the 
base. Its ducts open into the distal prostatic urethra. The PZ contains the majority (70%) of the 
glandular tissue in the normal prostate, and represents the most frequent site of prostate cancer 
(PCa) origin. It is also the predominant site for the occurrence of the PCa precursor lesion, 
prostatic intraepithelial neoplasia (PIN), including high grade PIN (HGPIN). This zone is the one 
most susceptible to inflammation 5 .
• The central zone (CZ) contains about 25% of the glandular tissue and is resistant to both 
carcinoma and inflammation. In comparison with the other zones, cells in the central zone have 
distinctive morphologic features: more prominent and slightly basophilic cytoplasm and larger 
nuclei displaced at different levels in adjacent cells. Recent findings suggest that this one 
originates embryologically from the inclusion of mesonephric duct cells into the developing 
prostate.  
• The transitional zone (TZ) contains the mucosal glands. It is composed of lobules of glands with 
shorter ducts compared to those reaching out to the PZ and is often separated from the PZ by an 
indistinct band of collagenous tissue, which becomes more pronounced as the TZ is expanded by 
benign prostatic hyperplasia (BPH). In the young, post-pubertal adult, architectural and histologic 
differences in the glands of the TZ and the PZ are not well defined. The TZ is the exclusively site 
of BPH in the human prostate. In older individuals, the parenchymal cells of this zone frequently 
undergo extensive division and form nodular masses of epithelial cells. Since this zone is in close 
proximity to the proximity to the prostatic urethra, causing difficulty in urination. This condition is 
known as BPH.  
• The periurethral zone contains mucosal and submucosal glands. In later stages of BPH this zone 
may undergo pathological growth, mainly from the stromal components. Together with the 
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glandular nodules of the transitional zone, this growth causes increased urethral compression and 
further retention of urine in the bladder.  
Histology 
Approximately 70% of the prostate consists of glandular elements, while the remaining 30% 
is a fibromuscular stroma. Normal prostatic gland is composed of three distinct cell types: 
secretory (luminal) cells, basal cells, and neuroendocrine cells. The secretory cells line the 
glandular ducts and have a polarized intracellular organization, which is lost during 
carcinogenesis. The predominant secretory cells are characterized by expression of androgen 
receptor (AR), cytokeratins 8 and 18, CD57, and prostate-specific antigen (PSA). The basal 
cells adjacent to the basal membrane, contain a small number of cells considered the stem 
cells for the prostate gland. They express cytokeratins 5 and 14, CD44, and low levels of AR 
6-8. Neuroendocrine (NE) cells of the prostate are spread among the epithelial cells and are of 
neurogeic origin. NE cells are androgen-independent and express chromogranin A and a 
variety of peptide hormones. NE cells have a role in both prostatic growth and differentiation 
as well as in the exocrine secretory process and pathogenesis of both prostatic cancer and 
hyperplasia 9, 10. The stromal cells in the prostate gland are composed of both smooth muscle 
cells and fibroblasts.  
The entire duct-acinar system, with the exception of the main lateral ejaculatory ducts, is lined 
by columnar secretory cells, separated from the prostatic stroma by a layer of basal cells 
belonging to the basement membrane 1-3. 
Secretions  
The ejaculate from the human prostate is a slightly acid (pH 6.5) serous fluid in which several 
major secretory products can be identified, notably acid phosphatase, citrate, zinc, soluble 
fraction proteins, carbohydrates, electrolytes, polyamines, hormones, lipids and growth 
factors 11, 12.
Up to 57 major protein groups, of which 27 non-serum proteins (i.e. presumably excluded by 
the epithelial cells) have been identified. Major prostatic-specific proteins are prostatic acid 
phosphatase (PAP), PSA, and prostate binding protein (PBP), which are expressed at pubertal 
and adult ages. Proteolysis is the major function of prostate secretion, being rich in 
exopeptidase and endopeptidase. The most extensively studied protease is PSA, also known 
as seminin, seminal protease or chymotrypsin-like protease 3, 13. 
PSA  
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This enzyme is secreted into the alveoli and is ultimately incorporated into seminal fluid. The 
alveoli secretion is pumped into the prostatic urethra during ejaculation by contraction of the 
fibromuscular tissue of the prostate. The fibrinolysin in the secretion serves to liquefy the 
semen. Normal individuals have a low serum concentration of PSA. Circulating PSA is 
produced by the liver, not by the prostate gland which, in normal individuals, releases PSA 
only into prostatic secretion. However, in prostate cancer, serum concentration of PSA 
increases. In this case, the additional PSA is produced and released into the circulation by the 
prostate gland. Therefore, the elevated levels of PSA are directly related to increased activity 
of the prostate cancer cells. Increased blood levels of PSA, as well as PAP, are used as 
markers of the presence and progression of the disease.  
Prostate Disorders  
There are three pathological processes affecting the prostate gland with sufficient frequency 
to merit discussion: inflammation, benign nodular enlargement, and tumours. 
Prostatitis  
The term prostatitis refers in its strictest sense to histological inflammation of the tissue of the 
prostate gland, although historically the term has been used loosely to describe a set of widely 
differing conditions. 
Incidence and prevalence: Prostatitis can affect men of any age, and it is estimated that 50% 
of men experience the disorder during their lifetime. Prostatitis is the most common 
urological disorder in men over the age of 50 and the third most common disorder in men 
younger than 50. According to the National Institutes of Health (NIH), prostatitis accounts for 
25% of all office visits involving the genitourinary system by young and middle-aged men 14.  
Nonbacterial prostatitis and prostatodynia are the most common diagnoses. Bacterial 
prostatitis (acute and chronic) accounts for less than 5-10% of cases. Acute bacterial 
prostatitis occurs most often in men under age 35, while chronic bacterial prostatitis primarily 
affects men between the ages of 40 and 70.  
Risk factors and causes: Risk factors include bladder outlet obstruction, (e.g., stone, tumour, 
BPH), diabetes mellitus, a suppressed immune system, and urethral catheterization. Some 
sexually transmitted diseases (STDs) increase the risk of developing bacterial prostatitis.  
Bacterial prostatitis is caused by the growth of bacteria normally found in prostatic fluid, such 
as Escherichia coli and Klebsiella. Urine reflux entering the prostate can also cause the 
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condition. There is no known cause of nonbacterial prostatitis or prostatodynia, but atypical 
organisms (e.g., viruses, chlamydial organisms) have been suggested. 
Classification: Prostatitis may be divided into several categories: acute and chronic bacterial 
prostatitis and chronic abacterial prostatitis and granulomatous prostatitis. According to the 
1999 NIH Classification 15, there are four categories of prostatitis: I: Acute prostatitis 
(bacterial); II: Chronic bacterial prostatitis; III: Chronic prostatitis/chronic pelvic pain 
syndrome: Subdivisions of IIIa (inflammatory) and IIIb (non-inflammatory) exist based on 
levels of pus cells in expressed prostatic secretions, but these subcategories are of limited use 
clinically; IV: Asymptomatic inflammatory prostatitis. 
Benign prostatic hyperplasia (BPH) 
BPH refers to the increase in size of the prostate in middle-aged and elderly men. It occurs 
almost exclusively in the transitional and periurethral zones. It is characterized by hyperplasia 
of prostatic stromal and epithelial cells, resulting in the formation of large, fairly discrete 
nodules in the periurethral region of the prostate. When sufficiently large, the nodules 
compress the urethral canal to cause partial, or sometimes virtually complete, obstruction of 
the urethra, which interferes with the urine flow. This leads to symptoms of urinary hesitancy, 
frequent urination, increased risk of urinary tract infections and urinary retention.  
Epidemiology. BPH can be seen in the vast majority of men around the world as they age, 
particularly in men over the age of 70 years. The prevalence of histologically diagnosed 
prostatic hyperplasia increases from 8 percent in men ages 31 to 40, to 40 to 50 percent in 
men ages 51 to 60, to over 80 percent in men older than 80 16.  
Etiology. Androgens (testosterone and related hormones) are considered to play a permissive 
role in BPH 17. Dihydrotestosterone (DHT), a metabolite of testosterone, is a critical mediator 
of prostatic growth and also of BPH. Therapy with 5-reductase inhibitor markedly reduces 
the DHT content of the prostate and in turn reduces prostate volume. There is growing 
evidence that both estrogens and inflammation play roles in the etiology of BPH 18, 19. 
Histopathology. The hallmark of BPH is nodularity attributable to glandular proliferation or 
dilation and to fibrous or muscular perforation of the stroma. The proportion of these elements 
varies from nodule to nodule, ranging from purely stromal fibromuscular nodules to 
fibroepithelial nodules with glandular predominance. Glandular proliferation takes the form of 
aggregations of small to large to cystically dilated glands, lined with two layers, an inner 
columnar and an outer cuboidal or flattened epithelium, based on an intact basement 
membrane. The diagnosis of BPH cannot usually be made on needle biopsy, as the histology 
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of glandular or mixed glandular-stromal nodules of BPH cannot be appreciated on this limited 
sampling. Two other histological changes are associated with BPH, namely foci of squamous 
metaplasia and small areas of infarction 20, 21.  
Prostate Cancer 
Epidemiology 
PCa remains one of the most common cancers afflicting men today. It is the third most 
common cancer in the world and the most common non-cutaneous malignant neoplasm, as 
well as the second cause of cancer death in men in Western countries, with a world age-
standardised rate of 104 cases per 100, 000 men 22. PCa is responsible for the death of 
approximately 30,000 men per year in the United States 23. In Sweden, approximately 10, 000 
new cases were detected in 2004 and 2,549 men died of PCa (Swedish National Board of 
Health and Welfare). The incidence has increased over the last two decades, with the PCa 
mortality rate remaining unchanged at a level of 59.03 cases per 100,000 men in 2003 in 
Sweden.   
Compared with the high rates in Western countries, PCa has low rates in Asian countries. 
However, with aging populations and increasing use of PSA screening, the incidence of 
prostate cancer in the high-risk countries has risen sharply in the past decade 24. It is revealing 
a more rapid increasing incidence of PCa in Asia than high-risk countries in recent data, such 
as in Japan, Singapore, and even in some Chinese cities, such as Beijing, Shanghai, and Hong 
Kong 24. The age-adjusted incidence rate has risen from 6.6 to 14.4 per 100,000 person-years 
from 1978 to 1997 in Singapore Chinese 24.  
Pathogenesis - the Possible Causes of Prostate Cancer
Less is known about the cause of PCa than about any other common cancer in the human 
body. A number of risk factors for PCa have been proposed, although the findings are often 
weak and controversial. The well-established risk factors include: increasing age, race, and 
family history of PCa. Risk factors that have no been well elucidated include: dietary, obesity, 
physical inactivity, hormonal, occupational, social, smoking, infection and/or inflammation, 
and sexual factors. 
Old age: It is uncertain why PCa is an almost inevitable consequence of old age. Perhaps 
there is breakdown of the immune system. It is also possible that the immune system is 
overwhelmed by an increased number of genetically altered cells in the body which occurs 
naturally with age. The number of altered or damaged cells may increase because of 
progressive failure of the enzymes acting on a cell-by-cell basis to deal with environmental 
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damage such as carcinogens, a high fat diet, and other factors. The cumulative exposure to 
mutagens and carcinogens could influence all of these factors, resulting in cancer. 
Family history and genetics: Heredity appears to be one of the most consistent and strongest 
risk factors for the development of PCa 25. Genetic studies suggest that a strong familial 
predisposition may be responsible for as many as 5-10% of PCa cases 26. A man's risk is two-
fold higher if one first degree relative such as a father or brother has PCa, and the risk is 5-11 
folds higher if 2 or 3 first degree relatives have PCa. 
Diet: An increased intake of animal fat and possibly red meat has been associated with an 
increased risk of PCa. In contrast, vegetables may protect against PCa. High intake of 
cruciferous vegetables containing the chemoprotective isothiocyanate sulforaphane was 
correlated with a diminished risk of PCa 27. But the relationship is complex and ill-defined, 
perhaps due in part to the influence of diet on the production of sex hormones, including 
increased androgen levels with high fat diets as well as the weak estrogen activity of soy 
compounds in Asian diets 28. Obesity and alcohol abuse may also be risk factors 29. 
Smoking: PCa is one of the few cancers in the human body which has not been strongly 
linked to smoking. 
Male hormones (testosterone):  The prostate requires hormones for growth and development, 
but hormones are also essential for cancer maintenance and growth. However, their role in the 
initiation of prostate cancer is unknown 30. Men whose testicles are never developed or are 
removed, never develop PCa 31. 
Sexual Activity: Investigators have suggested that sexual abstinence may contribute to PCa 
risk, but there is no consistent evidence to support this contention despite multiple studies 32. 
Recent studies suggest that prior sexual practices, exposure to sexually transmitted microbial 
agents and a history of prostatic infection may contribute to the risk of PCa 33.  
BPH: BPH is frequently seen in association with PCa, and there are a number of compelling 
similarities, including increasing incidence and prevalence with age, concordant natural 
history, and hormonal requirements for growth and development. However, no causal 
relationship has been established. 
Infections and inflammations (see below in detail): The cause of inflammation may be 
microbial infection or a noninfective physical, or chemical irritant, or a hormonally induced 
inflammation.  
Molecular pathology  
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PCa, like other types of cancer, is a result of the accumulation of both genetic and epigenetic 
alterations that transform normal glandular epithelium to preneoplastic lesions and then to 
invasive carcinoma. Recent advances in molecular research enable us to understand the 
functions of many of the protein products of oncogenes and tumour suppressor genes in great 
detail.  
Currently, it is difficult to determine whether PCa is caused by the inheritance of one or more 
specific genetic traits. Less than 10% of PCa are inherited; most appear to be sporadic 26. It is 
therefore suggested that the multiple clinical subsets presented may be the effects of different 
genetic mechanisms, and that multiple genetically controlled factors are involved in the 
evolution of sporadic tumours 34.
Loss of heterozygosity (LOH) and tumour suppressor genes: Cytogenetic studies reveal 
consistent chromosomal abnormalities in particular stages of PCa. Most of these abnormal 
chromosomal regions harbor several important genes involved in tumour development and 
progression. In PCa, chromosomal losses are more common than gains: losses of 
chromosomes 6q, 7q, 8p, 10q, 13q, 16q, 17, and 18q are particularly common events 35-37
(Table 1).  
Table 1. Abnormal chromosomal regions and the candidate genes involved in prostate cancer 
development and progression: 
Abnormal chromosomal regions  candidate genes
Chromosome 6q  Insulin-like growth factor II receptor (IGF2R) 
Cyclin C (CCNC) 
Chromosome 8, 8p23 and 8p12–22 NKX3.1.  
Chromosome 10q24 PTEN 
Chromosome 10q24–25 Negative regulator of c-myc proto-oncogene, MXI1 
Chromosome 11p11.2 Metastasis suppressor gene KAI1 
Chromosome 13q Retinoblastoma (RB) gene 
p15INK4B, p16/CDKN2, p21WAF1 and p27KIP1  
Chromosome 16q22 E-cadherin 
Chromosome 17p13 p53 
Chromosome 17q21.3–22 Metastasis-associated genes, nm-23 H1 and H2 
Data from Lijovic M 35, Karan D 36, De Marzo AM 37, De Marzo AM 38
Oncogenes: Information on the participation of oncogenes in PCa is limited, and the role of 
the expression or amplification of oncogenes remains unclear. c-myc, ras, c-erbB2 (Her-2 neu),
and Bcl-2 have received attention for their properties. 
• c-myc: Several studies have demonstrated increased c-myc expression in PCa and a significant 
correlation to Gleason grade 39.  
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• Ras: The frequency of ras mutations reported in PCa is variable. Mutations in K-, H-, and N-ras
were found in less than 5% of tumours in Western populations but were detected in 26% of 
prostate cancers in Japanese men 40, 41.  
• c-erbB2 (HER-2/neu). There is some controversy over the role of c-erbB2 in PCa. Some studies 
reported c-erbB2 over-expression in PCa and suggested that expression increases as PCa 
progresses to androgen independence 42. Other studies have failed to identify HER-2/neu 
amplification or overexpression in PCa 43.  
• Bcl-2, which encodes an anti-apoptotic protein, is overexpressed in approximately half of prostate 
cancers, particularly in androgen-independent tumours 44.  
DNA methylation: Aberrant epigenetic events such as DNA hypermethylation, DNA 
hypomethylation and histone acethylation have been observed in PCa. Apart from specific 
genetic mutations, recent studies have demonstrated silencing of tumour suppressor genes by 
promoter hypermethylation to be the most common feature in human tumours. Hypermethyla-
tion in the promoter regions of p14ARF, p15INK4b, p16INK4a, glutathione-S-transferase (GST), E-
cadherin and VHL genes has been described in PCa 45. The most common epigenetic change 
in PCa is hypermethylation of glutathione-S-transferase  (GSTP1), one of the major enzymes 
protecting against reactive oxygen species damage.  
Diagnosis 
Screening by digital rectal examination (DRE), biopsies and imaging: Patients with PCa 
show few early symptoms. Severe symptoms such as hematuria, urinary obstructive and bone 
pain are only present in advanced disease or cancer with metastases. Blood level of PSA, 
prostate palpation, and ultrasound-directed biopsy are the most common combinations of 
diagnostic tools 46. Digital rectal examination and imaging by ultrasound give information 
about the size and shape of the prostate. The most widely accepted indication for prostate 
biopsy is a PSA value in serum greater than 4.0 ng/ml 46. 10-12 cores of tissue from the gland 
under ultrasound guidance can be obtained from a single transrectal prostate biopsy. The 
biopsies are examined by a pathologist and routinely graded to the Gleason system.  
Gleason score 
A widely acknowledged method of grading the aggressiveness of PCa was developed by DF 
Gleason between 1969 and 1974. The Gleason system was based on histopathological data 
from over 4000 PCa biopsies and resections between 1960 and 1975 47-49. Architectural 
patterns seen at low magnification were recorded without preconception and independently 
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correlated with mortality data. Patterns that occurred frequently together and were associated 
with the same outcomes were grouped together, resulting in five grades (Fig 1):  
Fig 1. Gleason grade of prostate cancer
– Grade 1 (well differentiated), circumscribed mass of evenly spaced, closely packed, uniform 
shaped glands, with no evidence of infiltration of the stroma.  
– Grade 2 (well differentiated), some infiltration into the surrounding stroma and more variation in 
gland size and spacing, although this was limited. 
– Grade 3 (moderately differentiated), most common grade with more variation in size, shape, and 
separation of the glands, less defined boundaries, and less intervening stroma. 
– Grade 4 (poorly differentiated), fusion of the glands forming a solid anastamosing network with a 
ragged invasive edge. 
– Grade 5 (undifferentiated), characterised by a complete absence of gland formation with sheets or 
clusters of cells.  
Because of the histological variation within each tumour, two grades, the predominant, or 
primary, grade and the less extensive, or secondary grade, were recorded as the Gleason sum 
score in each case. For consistency, if only one grade was present, this was doubled. The 
primary and secondary grades showed similar correlations with mortality but the sum of these 
two grades showed the strongest correlation with cancer-specific mortality, hence, a low 
Gleason score ( 6) is indicative of a more indolent malignancy with a good prognosis 
whereas a high Gleason score (> 8) is associated with aggressive biological behaviour and an 
increased risk of occult systemic disease.  
Over many years the Gleason system has been shown to be a powerful predictor of prostate 
cancer behaviour and outcome after either prostatectomy 50, 51, radiotherapy, or in patients 
managed with surveillance 52. 
Biomarkers  
There are several groups of established biomarkers, but many of them are still under 
investigation, and a number of new promising markers are being identified by gene 
expression analysis, e.g. hepsin, AMACR, EZH2, cell cycle proteins, autoantibody signature 
53, 54
.  Among them, PSA, AMACR, and established tissue markers HMW (34E12) and p63, 
which are both basal cell markers, are routinely used in clinical laboratories. A triple antibody 
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cocktail staining, AMACR in combination with p63 and 34E12, is currently widely used in 
diagnosis of PCa.   
HMW 34E12: With the advent of immunohistochemistry, 34E12 has become an often 
useful adjunct in the diagnosis of prostatic adenocarcinoma 55. Specifically, 34E12 has been 
shown to highlight the sometimes inconspicuous basal cell layer in benign glands and has 
conventionally been considered negative in carcinomatous glands. 34E12 can occasionally 
be essential in differentiating carcinoma from its many benign mimickers, including adenosis, 
basal cell hyperplasia, and atrophy 56. 
Alpha-methylacyl-CoA-racemase (AMACR): AMACR is a recently discovered tumour 
marker whose expression is significantly upregulated in PCa. It has been shown to be a highly 
sensitive marker for the diagnosis of PCa. The majority of prostatic ductal and cribriform 
acinar carcinomas strongly expressed AMACR 57. Two antibodies, P504S and AMACR-p, 
were usually used for immunohistochemistry 57.   
P63: Basal cell marker. P63 is used as a tool to determine the state of the basal cell layer and 
to distinguish the regions of PIA from those of PIN and PCa 58.  
Alternative Treatments  
Despite recent advances in early diagnosis and treatment, PCa remains the second most lethal 
cancer type for men in the Western World 59, 60. Initially, the majority of prostate cancers are 
responsive to androgen ablation therapy, but most of the tumours eventually progress to the 
androgen-refractory state and then do not respond to hormonal treatment and often develop 
metastatic phenotypes 61. 
Prostatectomy is a surgical approach the treatment of PCa, used to remove all or part of the 
prostate. Typically, men with early-stage disease or cancer that is confined to the prostate will 
undergo radical prostatectomy, or surgical removal of the entire prostate gland plus some 
surrounding tissue 62. 
Radiation Therapy involves the killing of cancer cells and surrounding tissues with directed 
radioactive exposure, and is an initial treatment for PCa. Some forms of radiation therapy can 
also be used in men with advanced or recurrent PCa 63.  
Hormone Therapy is designed to stop testosterone from being released or to prevent the 
hormone from acting on the prostate cells. Hormone therapy plays an important role in men 
with advancing PCa, and it is increasingly being used before, during, or after local treatment 
as well. The majority of cells in PCa respond to the removal of testosterone. But some cells 
grow independently of testosterone, and therefore remain unaffected by hormone therapy. As 
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these hormone-independent cells continue to grow unchecked, over time, hormone therapies 
have less effect on the growth of the tumour. Hormone therapy is therefore not a perfect 
strategy, but remains an important step in the process of managing advancing disease, and is 
likely to be a part of therapeutic regimen at some point in recurrent or advanced PCa 62, 64. 
New Therapies  
Chemotherapy: Systemic chemotherapy may be of value for men with advanced high stage 
PCa who have failed to respond to hormone therapy. However, all chemotherapeutics, either 
as single agents or in combination, are associated with toxicity 65. Recently, doxetaxel was 
shown to improve survival in hormone refractory PCa 66.
Thermal therapy: Direct application of high temperatures will destroy cancer cells, and this 
method has been exploited with laser therapy, microwave hyperthermia, and electrocautery 
and electrovaparization. These techniques are of proven value for treatment of BPH, while 
none has been shown to be of value in PCa 67.
Gene therapy: Intensive research about the molecular changes in androgen-independent PCa 
led to the identification of several interesting genes, which may be useful as targets for gene 
therapy. In fact, there is a broad range of different gene therapy approaches in the field of PCa, 
some of which have already progressed to clinical evaluation in patients (Phase I/II clinical). 
These agents have aimed to be immunomodulatory (i.e., to stimulate tumour recognition by 
the immune system), to target an oncogene, replace a defective tumour-suppressor gene, or to 
directly lyse tumour cells. The Granulocyte-macrophage colony-stimulating factor (GM-CSF) 
gene-engineered prostate cancer vaccine (Prostate Cancer GVAX® Vaccine) has been used in 
a phase II study of hormone refractory prostate cancer and suggested that the Vaccine delays 
progression and prolongs survival in patients with bone metastatic prostate cancer 68.
Anti-angiogenesis therapy: Several anti-angiogenic agents are currently under investigation 
in clinical trials, and the results are promising 69, 70. One advantage of anti-angiogenic therapy 
over conventional therapy is the low frequency of drug resistant mutations in endothelial cells. 
Current anti-angiogenic strategies target endothelial cells either directly, by inhibiting their 
proliferation and migration or inducing apoptosis, or indirectly, by inhibiting the production 
of angiogenic factors by tumour cells. Therapeutic strategies include the delivery of 
endogenous inhibitors of angiogenesis, agents that prevent the degradation of the basement or 
extracellular membrane, agents that interfere with or block the action of pro-angiogenic 
factors, and small molecule inhibitors of angiogenic factor receptors found in prostate cancer 
71.
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Tyrosine Kinases inhibition: Tyrosine kinases have been implicated in prostate epithelial 
cell transformation and tumour progression. Implicated tyrosine kinases include fibroblast 
growth factor receptor (FGFR), epidermal growth factor receptor (EGFR), and platelet-
derived growth factor receptor (PDGFR). It has been reported that tyrosine kinase inhibitors 
(TKIs) assert their anti-tumour effects against PCa by a hormone-independent mechanism 72.
The combination of TKIs therapy and anti-hormone therapy can be synergistic 73.  
Androgen receptor (AR) 
Androgens are indispensable for the development and regulation of the male reproductive 
system and are also involved in the development of PCa 74. The effects of androgens are 
mediated through the AR.  
AR, a member of the subfamily of steroid receptors, has a pivotal role in the regulation of 
prostate growth and secretory responses. After binding of its ligand, the AR undergoes a 
conformational change and acquires an active form which regulates transcription of androgen-
responsive genes. Thereby its functional activity is modulated by interactions with receptor-
associated tissue-specific co-regulatory proteins, called co-activators and co-repressors 75, 76.  
It is well known that PCa is driven by androgen. Indeed, neither cancer nor hypertrophy will 
occur in the absence of androgen.  Men castrated before puberty or those with 5-reductase 
deficiency do not develop PCa 77. Interestingly, high levels of AR are associated with 
aggressive clinicopathologic features and with decreased biochemical recurrence-free survival 
in PCa patients treated with radical prostatectomy 78. These observations are consistent with 
reports demonstrating that increases in AR mRNA and protein levels are both necessary and 
sufficient to convert PCa growth from the hormone-sensitive to hormone-refractory stages, 
and is dependent on a functional AR ligand-binding domain 79. It may be that activity of AR 
and levels of AR, rather than testosterone, are the driving forces for PCa. It was shown that 
low levels of testosterone was associated with higher androgen receptor density in PCa, as 
well as higher Gleason score 78.   
AR in androgen-independent PCa 80: Analysis has shown that AR continues to be 
expressed in androgen-independent PCa and that AR signalling remains intact, as 
demonstrated by the expression of the AR regulated gene, PSA. Androgen-independent PCa 
has demonstrated a variety of AR alterations, including AR amplification, AR point mutation, 
and changes in expression of AR co-regulatory proteins 81. These AR changes result in a 
“super AR” that can respond to lower concentrations of androgens or to a wider variety of 
agonistic ligands. There is also evidence that AR can be activated in a ligand independent 
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fashion by compounds such as growth factors or cytokines working independently or in 
combination, such as insulin-like growth factor-1( IGF-1), keratinocyte growth factor (KGF), 
and epidermal growth factor (EGF) 80.  
AR down-regulation: Studies have shown the AR expression decreased after castration in 
the CWR22 human prostate cancer xenograft model 82. AR expression decreased from 100% 
before androgen deprivation therapy to 88% after ADT, and the loss of AR was associated 
with a tendency to high Ki-67 index (from 17.4% to 26.3%). Reduced expression of AR 
appeared in 20–30% of androgen-independent PCa 83. Methylation of the AR gene promoter 
has been reported in advanced hormone-independent PCa tissue and may be one of the causes 
of AR down-regulation in PCa 84. AR down-regulation is more common in PCa cells. In 
androgen-independent PCa cell lines, such as DU145 and PC3, the loss of AR expression 
often occurs during the clinical evolution of PCa 83, 85. In vivo studies have shown that AR 
mRNA and protein levels in the LNCaP cells could be down-regulated by EGF 86, basic 
fibroblast growth factor (bFGF) 87, and tumour necrosis factor  (TNF) 88. These results 
suggested that inflammatory cytokines may play roles in the initiation of an androgen-
independent state in PCa through their ability to inhibit AR sensitivity in PCa. Moreover, IL-
1 is also responsible for down-regulation of AR protein expression 89.  
Chronic Inflammation and the Pathogenesis of Neoplasia 
Epidemiology and Clinical Studies
In 1863, Virchow noted leucocytes in neoplasitc tissues and hypothesized that malignant 
neoplasms occurred at sites of chronic inflammation. Virchow reasoned that various "irritants" 
caused tissue injury, inflammation, and increased cell proliferation 90, 91.  
Recently, the association between inflammation and cancer was illustrated in epidemiological 
and clinical studies 90-92. There is increasing evidence supporting the association between
chronic inflammation and cancer development. For instance, the risk of colorectal cancer was 
10-fold greater when associated with inflammatory bowel disease, such as ulcerative colitis
and Crohn's disease 90, 93. Moreover, the control of colitis by certain anti-inflammatory agents 
reduced colon cancer incidence93. Persistent gastric infection with Helicobacter pylori and 
stomach cancer 94, human papillomavirus (HPV) infection and cervical cancer 90,95 are also 
examples of such process.  
The proportion of cancer deaths attributable to infectious agents has been estimated to range 
from 20% to 25% in developing countries and 7% to 10% in more industrialized countries, 
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that meaning about 1.8 million cases of cancer were attributable to infectious agents in the 
year 2000 90-92 (Table 2) 
Table 2. Chronic Infection and/or Inflammation and Human Tumours 
Causal Mechanisms Types of Tumour 
Helicobacter pylori and chronic gastritis Adenocarcinoma of stomach 
Epstein-Barr virus B-cell lymphoma 
Non-Hodgkin lymphoma 
Hodgkin lymphoma 
Nasopharyngeal carcinoma 
Human papillomavirus Anogenital carcinoma 
Oropharyngeal carcinoma 
Hepatitis B or C virus Hepatocellular carcinoma 
HIV/AIDS Non-Hodgkin lymphoma 
Kaposi sarcoma 
Liver flukes (eg, Clonorchis sinensis) Cholangiocarcinoma 
Schistosoma haematobium Squamous carcinoma of urinary bladder 
Gastroesophageal reflux Adenocarcinoma of the distal esophagus and 
gastric cardia 
Ulcerative colitis Adenocarcinoma of the large intestine 
Crohn granulomatous colitis Adenocarcinoma of the large intestine 
Chronic obstructive lung disease Carcinoma of the lung 
Chronic lung infections Carcinoma of the lung 
Chronic diffuse infiltrative lung diseases 
(eg, asbestosis, silicosis) 
Carcinoma of the lung 
Chronic cholecystitis Gallbladder carcinoma 
Inflammatory atrophy of prostate Prostate carcinoma
Data from Balkwill F 90, Coussens LM 91, Schottenfeld D 92
Causes of Inflammation 
The cause of inflammation may be microbial infection, such as Helicobacter pylori in gastric 
cancer, hepatitis B virus (HBV) in hepatocellular carcinoma, or a non-infective physical and/or 
chemical irritant, such as gallstones in gallbladder cancer. In addition, autoimmune and 
inflammatory reactions of uncertain etiology were also be involved (Table 2). 
  
Epidemiologic Support for a Relation between Inflammation and Prostate Cancer  
There is evidence indicating that prostatic inflammation may contribute to prostate growth 
either in terms of BPH or PCa changes and, therefore, several clinical prevention trials for 
neoplasms have focused on antioxidants or anti-inflammatory agents. Several clinical trials 
have demonstrated an association between chronic inflammation, including prostatitis and 
sexually transmitted infections/diseases (STDs), and PCa. 
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Prostatitis: Various epidemiological studies have shown a significant association between 
prostatitis and prostate carcinoma 96-98. A cross-sectional analysis from a prospective cohort 
study of 5821 men aged 65 years found positive associations for a self-reported history of 
prostatitis with a history of PCa 96. Another case-control study investigated 409 cases at 
diagnosis of PCa and 803 control subjects from 1980 to 1996 97. The odds ratio of PCa in men 
with any type of prostatitis was 1.7, with acute bacterial prostatitis was 2.5, with chronic 
bacterial prostatitis 1.6, and with chronic pelvic pain syndrome 0.9. Therefore, infectious 
prostatitis might be associated with PCa. A meta-analysis of 11 case-control studies revealed 
a statistically significant summary odds ratio of prostate cancer of for ever having had 
prostatitis 98. They found an increased risk of PCa among men with a history of prostatitis 
(OR = 1.6), particularly in population-based case-control studies (OR = 1.8). More recently, 
MacLennan et al.99 analyzed 177 prostate needle biopsies from patients with clinical 
parameters suspicious for malignancy, including 144 patients with and 33 without chronic 
inflammation in the initial biopsies. In repeated biopsies within 5 years, in patients with 
chronic inflammations, 29 new PCa were diagnosed, representing a new cancer incidence of 
20%. In contrast, in 33 patients initially showing no inflammation, PCa was subsequently 
found in 2 (6%).  
However, some studies show no compelling evidence to support the hypothesis that prostatitis 
is a risk factor for PCa97.Karakiewicz et al. 100 examined the association between inflamma-
tion and coexistent PCa, as well as HGPIN, in 4,526 patients assessed with systematic 
prostate biopsies. Results showed that men with chronic inflammation exhibited HGPIN 
(2.7% vs. 20.3%, p < 0.01) and PCa (13.6% vs. 43.5%, p < 0.01) less frequently than their 
counterparts without chronic inflammation. In the study, the OR of 0.20 indicated that 
inflammatory aspects on needle biopsy are 80% less likely to appear with coexistent PCa than 
men without chronic inflammation. Similar results were found between inflammation and 
HGPIN (OR = 0.11) 100.  
Goldstraw et al. analyzed the possible confounding factors leading to these different results in 
epidemiologic studies 101: (1), the true incidence of prostatitis or prostatic inflammation is 
uncertain. Men who have prostatitis may have the condition without clinical symptoms; (2), 
symptomatic men with prostatitis are more likely to be screened for PCa or to undergo a 
needle biopsy. Therefore, PCa may be over-diagnosed in this population.  
Sexually transmitted infections/diseases (STDs): STDs have been inconsistently associated 
with PCa, with positive associations being reported with syphilis, gonorrhoea and HPV 
infections in various studies 102. Dennis and Dawson 103 found a greater relative risk of PCa 
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among men with a history of STDs, using both random and fixed-effects models (OR = 1.4; 
17 studies), especially for syphilis (OR = 2.3; six studies). These results indicate an 
association between PCa and STDs, suggesting that infections might represent one 
mechanism through which PCa develops. A similar meta-analysis of 29 case-control studies 
showed a significantly high odds ratio for PCa for any STD (OR = 1.48), gonorrhoea 
(OR = 1.35) and HPV (OR = 1.39) 104. Another study demonstrated that the OR between 
sexually transmitted (most evidence involves syphilis and gonorrhea) prostatic infections and 
PCa was significant (OR = 1.4; p = 0.003) in a meta-analysis 103. 
The causes of prostatic inflammation 
Although various epidemiological studies have shown a significant association between 
prostatitis and prostate carcinoma, the causality in these epidemiological studies is unclear, 
because of potential confounders. There are various potential sources for the initial event, 
including direct infection, urine reflux inducing chemical and physical trauma, dietary factors, 
estrogens, and combinations of two or more of these factors. Furthermore, any of these could 
lead to a disruption of immune tolerance and the development of an autoimmune reaction to 
the prostate.
Infectious agents: Many different pathogenic organisms have been observed to infect and 
induce an inflammatory response in the prostate 38. These include sexually transmitted 
organisms 102, such as Neisseria gonorrhoeae, Chlamydia trachomatis 105, and non-sexually 
transmitted bacteria such as Propionibacterium acnes and those known to cause acute and 
chronic bacterial prostatitis, primarily Gram-negative organisms such as Escherichia coli. 
Although each of these pathogens has been identified in the prostate, the extent to which they 
typically infect this organ varies 38.  
Bacterial DNA sequences were detected in 19.6% of patients with PCa 106. In another analysis 
with prostate samples from organ donors, PCa or BPH, there was a strong association 
between inflammation and positive bacterial 16S rRNA gene PCR findings 107. Concordance 
between inflammation and positive PCR results suggests that bacteria might often have a role 
in histologically inflammatory prostatitis caused by bacteria detectable through 16S rRNA 107.
Recently, a study of mouse model of chronic bacterial prostatitis induced by E. coli suggested 
that chronic bacterial prostatic infection and inflammation can lead to neoplastic tissue 
alterations in the prostate: from varying degrees of atypical hyperplasia to severe dysplasia in 
the prostate. In particular chronic inflammation could produce histologic changes similar to a 
PIN lesion 108.  
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Viruses can also infect the prostate.  Human papillomavirus (HPV), human herpes simplex 
virus type 2 (HSV2), cytomegalovirus (CMV) and human herpes virus type 8 (HHV8) have 
been detected in the prostate 38, 109. How frequently these agents infect the prostate, and 
whether they elicit an inflammatory response, is largely unknown.  
Estrogens: Estrogenic exposures may be another cause of prostate inflammation and PCa. 
Increased levels of estrogens have long been linked to the development of PCa 110. Estrogens 
affect the growth and development of the prostate, by direct effects mediated by estrogen 
receptor (ER)- in the stroma, and ER- in the epithelium or through indirect routes 110, 111. 
Brief exposure of rats to high-dose estrogen during the neonatal period result in an “imprinted 
state” or “developmental estrogenization” in which there are developmental defects, including 
a reduction in prostatic growth. This treatment also results in the development of lobe-specific 
inflammation, hyperplasia and dysplasia or PIN 111. Therefore, it is quite plausible that 
chronic inflammation in the adult human prostate might reflect an autoimmune reaction 
caused, at least in part, by estrogens. In adult animals, exposure to estrogens with or without 
DHT also results in prostate inflammation 112, 113. 
Dietary factors: Epidemiological studies have revealed a link between PCa incidence and 
mortality and the consumption of red meat and animal fats 114, 115. One mechanism could be 
related to the formation of heterocyclic amines (HCAs). Exposure of rats to dietary 2-amino-
1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) results in carcinomas of the intestine in both 
sexes, in the mammary gland in females and in the prostate in males 116. More interestingly, a 
processes from atrophy in prostate to HGPIN was observed directly in the atrophic epithelium 
116.  
Urine reflux, chemical, physical trauma and others: Chemical irritation from urine reflux 
has been proposed as an etiological agent for chronic inflammation in the prostate 117. A study 
suggested that in mice the bacterial colonization of the prostate, possibly through the reflux of 
urine into the prostatic ducts of the peripheral zone, could play a role in the genesis of chronic 
inflammation and in prostatic tumorigenesis 38. Urine reflux of injurious chemicals can 
function in conjunction with infectious agents to increase prostate inflammation 118. Another 
manner by which prostate inflammation might occur is the development of corpora amylacea 
119. Corpora amylacea have been proposed to contribute to prostate inflammation, persistent 
infection and prostate carcinogenesis, since they are frequently observed adjacent to damaged 
epithelium and focal inflammatory infiltrates. Intraprostatic spermatozoa is another cause of 
prostate inflammation and is related to prostate atrophy 38,120.  
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Inflammatory Microenvironment Associated with the Subsequent Development of Cancer 
Chronic inflammation is characterized by sustained tissue damage, damage-induced cellular 
proliferation, and tissue repair. Histopathological features of chronic inflammation include the 
predominance of macrophages and lymphocytes, proliferation of nurturing structurally 
heterogeneous and hyperpermeable small blood vessels, fibrosis, and necrosis 121. The tumour 
inflammatory microenvironment is characterised by the presence of host leucocytes, high 
levels of reactive oxygen and nitrogen species both in the supporting stroma and in tumour 
areas, and inflammatory cytokine network 90, 91.  
Host leucocytes. Macrophages, mast cells, neutrophils, eosinophils, lymphocytes, and 
dendritic cells have been found to be key components in the epithelial-originated tumours 122.  
• Tumour-associated macrophages (TAM) contribute to tumour development through several 
mechanisms. TAMs release interleukin (IL)-10 and prostaglandin E2 (PGE2), which suppress 
antitumour response 123. TAMs also facilitate tumour growth by releasing angiogenic factors, such 
as VEGF, endothelin-2, and urokinase-type plasminogen activator 121, 124. TAMs produce IL-1, 
which up-regulates VEGF transcription 125. TAMs also facilitate tumour cell invasion and 
metastasis by releasing matrix metalloproteinases (MMP-2 and MMP-9) 126. In addition, TAMs 
induce TNF- and iNOS, which damage DNA and inhibit DNA repair. Moreover, TAMs release 
epidermal growth factor and other epidermal growth factor receptor family ligands to promote 
tumour cell proliferation and migration 123.  
• Activated mast cells generate angiogenic growth factors, such as VEGF/vascular permeability
factor and bFGF, specific angiogenic regulators histamine and heparin, MMP-9, and mast cell–
specific proteases MCP-4 and MCP-6 127, 128. Therefore, activated mast cells are suggested to be 
involved in tumour angiogenesis, invasion, and metastasis. Inflammatory mast cells also enhance
tumour progression by releasing cytokines and chemokines.  
• Tumour-associated neutrophils enhance tumour angiogenesis, invasion, and metastasis in a 
similar manner to TAMs and mast cells 128. Neutrophils may also play a role in genetic instability
of tumours 128.  
• T-lymphocytes are recruited to tumours by a series of chemokines. At the premalignant lesion 
stage in a skin cancer model, the knockout of T cells resulted in decreased leukocyte infiltration
and reduced levels of MMP-9 129. The increase of CD4+ T cells was consistently positively 
correlated with poor prognosis in both renal cell cancer and colorectal cancer 130.  
• Tumour-associated dendritic cells (TADC) have an immature phenotype with defective ability 
to stimulate T cells 90.  
Reactive oxygen and nitrogen species: Chronic inflammation and the metabolic products of 
phagocytosis are often accompanied by the excessive formation of reactive oxygen and 
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nitrogen species that are potentially damaging to DNA, lipoproteins, and cell membranes. 
Inflammatory cells also release metabolites of arachidonic acid, or eicosanoids, including
prostanoids or prostaglandins and leukotrienes. Cyclooxygenase (COXs) are key enzymes that 
control rate-limiting steps in prostaglandin synthesis.  
Table 3. Key Molecular Players Linking Cancer to Inflammation 
Potential linkers Functions in linking inflammation to cancer 
Cytokines 
IL-6 Promote tumour growth 
TNF- Induce DNA damage and inhibit DNA repair 
 Promote tumour growth 
 Induce angiogenic factors 
Chemokines Promote tumour cell growth 
Facilitate invasion and metastasis by directing tumour cell migration and promoting 
basement membrane degradation 
NF-B Mediate inflammation progress, promoting chronic inflammation 
 Promote the production of mutagenic reactive oxygen species 
 Protect transformed cells from apoptosis 
 Promote tumour invasion and metastasis 
 Feedback loop between proinflammatory cytokines 
iNOS Downstream of NF-B and proinflammatory cytokines 
Induce DNA damage and disrupt DNA damage response 
 Regulate angiogenesis and metastasis 
COX-2 Produce inflammation mediator prostaglandins 
 Promote cell proliferation, antiapoptotic activity, angiogenesis, and metastasis 
HIF-1 Promote chronic inflammation 
 Induced by proinflammatory cytokines through NF-B 
 Enhance the glycolytic activity of cancer cells 
 Contribute to angiogenesis, tumour invasion, and metastasis by transactivating VEGF
STAT3 Activated by proinflammatory cytokines 
Promote proliferation, apoptosis resistance, and immune tolerance 
Nrf2 Anti-inflammatory activity 
Protect against DNA damage 
NFAT Regulate proinflammatory cytokine expression 
  Required in cell transformation 
Date from Lu H 121. HIF-1, hypoxia-inducible factor-1alpha; STAT3, Signal Transducer and Activator of 
Transcription 3; Nrf2, NF-E2-related factor-2; NFAT, nuclear factor of activated T-cells. 
Inflammatory cytokine network: The cytokine network is rich in inflammatory cytokines 
(lymphokines, ILs, interferons), growth factors, stress proteins, and chemokines, which might 
be produced by the tumour cells and/or tumour-associated leucocytes and platelets, and which 
may directly or indirectly contribute to malignant progression. This cytokine network may 
influence survival, growth, mutation, proliferation, differentiation, and movement of both 
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tumour and stromal cells. Moreover, these cytokines can regulate communication between 
tumour and stromal cells, and tumour interactions with the extracellular matrix 90, 91 (Table3). 
Mechanism of Inflammation and/or Infection and Carcinogenesis of Prostate  
Genetic aspects. Nelson et al. analyzed the molecular basis of the association between 
inflammation and prostate proliferative diseases from a genetic view point 131. PCa has the 
greatest inherited contribution of any common cancer. PCa genes appear to confer increased 
susceptibility to PCa in certain families. The possibility that viral or bacterial infections or 
inflammation might lead to PCa has been linked with the identification of two candidate 
susceptibility genes familial PCa genes 131. RNASEL, which encodes an enzyme that 
degrades viral RNA on viral infection, is linked to PCa in specific families 132 and is 
associated with an increased PCa risk 133. MSR1 encodes subunits of a macrophage-scavenger 
receptor capable of binding bacterial lipopolysaccharides 131. MIC1 gene is a member of the 
TGF superfamily and is recognized to have an important role in inflammation by regulating 
macrophage activity 131. In a study a series of MSR1 mutations appeared to be linked to PCa 
susceptibility in some families at high risk for PCa 134.
Oxidative stress: Chronic inflammation can induce proliferative events and posttranslational 
DNA modifications in prostate tissue through oxidative stress. In fact, repeated tissue damage 
and oxidative stress related to this event may provoke a compensatory cellular proliferation 
with the risk of hyperplastic growth or also of neoplastic modifications 135, 136. It is well 
accepted that regions of prostatic inflammation can generate free radicals, such as nitric oxide 
(NO) and various species of oxygen. In particular, macrophages and neutrophil infiltrations 
provide a source of free radicals that can induce hyperplastic or precancerous transformations 
through the oxidative stress to the tissue and DNA 135. The inducible NO synthase (iNOS) is 
the principal factor activating reactive nitrogens that can damage cells 137. Gradini et al. 138
characterized NOS expression in human prostate tissue and, particularly for iNOS, they found 
an increased immunostaining in the epithelial cells of cases with BPH and more with HGPIN 
and PCa, when compared to normal tissue. NO also enhances COX activity 135.  
Glutathione-S-transferase activity: Normally, prostate tissue is protected by oxidative stress 
reactions, free radicals, and highly reactive oxygen species by the superoxide-dismutase and 
the GST enzymes systems. GST gene methylation produces the loss of this protective enzyme 
system and it could be implicated in the transition from inflammation to preneoplastic lesions 
and therefore to PCa 135. Lee, et al 139 identified GST methylation in nearly 70% of HGPIN 
lesions and in >90% of PCa. 
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COX-2 and Cancer 
Cyclooxygenase 
Cyclooxygenase (COX), also referred to as prostaglandin endoperoxide synthase, is a key 
enzyme in the conversion of arachidonic acid to prostaglandins (PGs) and other eicosanoids. 
It exists as three isoforms, COX-1, COX-2, and COX-3. COX-1 and COX-2 are encoded by 
separate genes located on separate chromosomes 140. They are highly related at the DNA, 
RNA, and protein level. COX-1 and COX-2 consist of 576 and 587 amino acids, respectively, 
and they share approximately 60% primary sequence homology. COX-1 and COX-2 exist as 
integral membrane glycoprotein homodimers and are found on the luminal surfaces of the 
endoplasmic reticulum and nuclear envelope 141, 142. Traditional NSAIDs, such as aspirin and 
ibuprofen, act by inhibiting COX activity.  
Although COX-1 and COX-2 genes are similar, they are under profoundly different 
mechanisms of control and fulfil different physiological functions. COX-1 is essentially a 
“housekeeping gene”, expressed constitutively in most normal tissues and is required for their 
normal physiological function. It is important for mediating various normal physiologocial 
processes, including the preservation of renal blood flow and function, platelet aggregation 
and hemostasis, and cytoprotection of the gastrointestinal mucosa. COX-2, on the other hand, 
is an “immediate to early gene” 143, 144. It is frequently undetectable at baseline in normal 
tissues, but can be induced in response to mitogenic agents such as growth factors, hormones, 
bacterial endotoxin, tumour promoters, cytokines, hypoxia, and its role has been connected to 
inflammation and carcinogenesis 145. The third form of COX, termed COX-3, has been 
identified. It encodes a protein with a completely different amino acid sequence than COX-1 
or COX-2, and its exact function is still to be determined 146.  
COX-2 expression in human tumours 
Expression of the COX-2 is elevated in a variety of human malignancies and premalignant 
lesions, including colon, head and neck, lung, bladder, stomach, breast, and prostate cancer. In 
colon cancer, for example, several studies reported an inverse correlation between colon 
cancer incidence and regular use of NSAIDs and NSAIDs are known to function by inhibiting 
COX enzyme activity 147, 148. COX-1 levels were not increased in colorectal tumours. In 
contrast, striking COX-2 upregulation was observed in colon cancer and in some adenomas 
149, 150. Increased COX-2 staining correlated with larger polyp size and progression to invasive 
carcinomas as well 149, 150. Treatment with the NSAIDs causes a decrease in the size and 
number of polyps in familial adenomatous polyposis patients 151. Thus, overexpression of 
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COX-2 appears to contribute to colorectal cancer and COX-2 inhibitors are likely to be useful 
chemopreventive agents.  
COX-2 overexpression in gastric cancer is another example. Normal gastric mucosa scarcely 
expresses COX-2.  It has been shown that H pylori infection induces COX-2 mRNA/protein 
levels with the production of PGE2 in gastric premalignant and malignant lesions
152-154
. The 
COX-2 expression also correlates with to poor prognostic parameters, tumour size, depth of 
invasion, lymph node metastasis, lymphatic invasion, and angiogenesis 155, 156. COX-2 
expression also correlated with p53 accumulation, indicating that COX-2 is induced by p53-
mediated activation157. 
COX-2 and inflammogenesis of cancer 
There are increasing evidences from molecular, animal, and human investigations support the 
hypothesis that aberrant induction of COX-2 and up-regulation of the prostaglandin cascade 
play a significant role in carcinogenesis, and reciprocally, blockade of the process has strong 
potential for cancer prevention and therapy 158. Supporting evidence includes:  
1) Expression of constitutive COX-2-catalyzed prostaglandin biosynthesis is induced by 
most cancer-causing agents, including mitogens, growth factors, proinflammatory 
cytokines, microbial agents, tumour promoters, essential polyunsaturated fatty acids, 
and other epigenetic factors 158, 159. 
2) COX-2 expression is a characteristic feature of both neoplasms and premalignant 
neoplasms, including in colon cancer and some adenomas 149, 150; in pancreatic 
carcinoma and its pre-malignant lesion, intraductal papillary mucinous adenomas 160; in 
esophageal adenocarcinoma and Barrett’s esophagus, as well as dysplasia 161; in gastric 
cancer and its premalignant lesions153; and in prostate cancer and HGPIN 162-171.   
3) Most of the essential features of carcinogenesis (mutagenesis, mitogenesis, angiogenesis, 
reduced apoptosis, metastasis, and immunosuppression) are linked to COX-2-driven 
PGE-2 biosynthesis 172-175.
4) Animal studies show that COX-2 up-regulation is sufficient to stimulate the 
transformation of normal cells to invasive cancer and metastatic disease 176, 177.  
5) Non-selective COX-2 inhibitors, such as aspirin and ibuprofen, and selective COX-2 
inhibitors, such as celecoxib, reduce the risk of human cancer and precancerous lesions 
178, 179.  
Proposed mechanism for the role of COX-2 in carcinogenesis  
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Multiple lines of compelling evidence support that COX-2 plays a crucial role in 
carcinogenesis. Since COX-2 is a PG synthase, the most obvious consequence of COX-2 
overexpression is increased PG production, and indeed high PG levels have been detected in 
many cancers. PGs are believed to be important in the pathogenesis of cancer because of their 
effects on cell proliferation, angiogenesis, immune surveillance, and apoptosis 171, 180 (Fig 2).  
Fig 2. Schematic representation of roles of COX-2 in carcinogenesis. Adjusted from Chun181, Pruthi171, 
and Zha180
PGs stimulate proliferation. Inappropriate stimulation of cellular proliferation by PGs may 
contribute to tumorigenesis. Enhanced PG synthesis may contribute to carcinogenesis in 
several ways, including direct stimulation of cell growth 172. PGE can stimulate mitogenesis in 
Balb/c 3T3 fibroblasts in synergy with epithelial growth factor (EGF) 172. Both PGE1 and 
PGE2 stimulate proliferation of mammary epithelial cells in the presence of EGF 182, 183.
Effects on angiogenesis. Tumour angiogenesis includes destabilization of pre-existent blood 
vessels, proliferation of vascular endothelial cells, invasion by endothelial cells into the 
extracellular matrix (ECM) and finally the migration and positioning of endothelial cells. 
COX-2 is known to play an important role in tumour-induced angiogenesis through the 
synthesis of angiogenic PGs such as PGE2, which induces matrix metalloproteinase (MMP) 
and VEGF 184-186. Subsequently, numerous studies showed co-localization of angiogenesis 
factors, such as VEGF, PDGF, bFGF and TGF- with COX-2 by immunohistochemical 
staining in different cancer types 187. In breast cancer, the density of microvessels was higher 
in patients with COX-2 expression than in those without COX-2 expression 188. Studies of 
colon cancer cell lines co-cultured with vascular endothelial cells demonstrated that COX-2 
supported angiogenesis at multiple steps both directly and indirectly 189. First, COX-2 up-
regulation leads to PGs production, and PGs have distance roles for angiogenesis. Second, 
overexpression of COX-2 in tumour cells directly stimulates the production of angiogenic 
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factors, including VEGF, PDGF, bFGF and TGF-, from these cells 189, 190. Through these 
angiogenesis mediators and their receptors on the endothelial cells, COX-2 increased vascular 
permeability and induced endothelial cell proliferation and migration. In breast cancer, the 
density of microvessels was higher in patients with COX-2 expression than in those without 
COX-2 expression. COX-2 expression was also associated with the LN metastasis 173. 
COX-2 mediated resistance to apoptosis. The suppression of apoptosis associated with 
COX-2 overexpression could be an important factor in tumorigenesis, although the precise 
mechanistic basis remains uncertain. The first hint came from the observation that NSAIDs 
could induce apoptosis in cultured cell 191. Since then numerous studies using cultured cells 
and animal models have supported a role for COX-2 in promoting cell survival under 
unfavourable growth condition 192. Several hypotheses have been advanced to account for 
suppression of apoptosis in response to COX-2 overexpression. The ability of PGE2 to inhibit 
apoptosis caused by a selective COX-2 inhibitor, and concomitantly to induced Bcl-2, 
suggests that PG-mediated upregulation of Bcl-2 may suppress apoptosis 192. Multiple 
NSAIDs, including selective COX-2 inhibitors, induce apoptosis in a variety of cells 193. The 
further studies have shown that NSAIDs stimulate apoptosis may via both COX-dependent 
and -independent mechanisms 194.  
Immune suppression. PGs do not act as mitogens for all cell types, and in fact depress 
proliferation of some cells, particularly those immune cells 174, 195, and thereby contribute to 
the immune suppression. PGE2 inhibits T and B cell proliferation and cytokine synthesis, and 
diminishes the cytotoxic activity of natural killer cells. PGE2 also inhibits the production of 
TNF while inducing IL-10 production, which itself has immunosuppressive effects 175, and 
inhibit antigen processing by dendritic cell 174. Thus, PG-mediated immune suppression may 
contribute to tumorigenesis, since this may allow tumours to avoid immune surveillance. 
Effects on cell motility and invasiveness. PGs may have effects on cell motility and 
adhesion. COX-2 expression leads to increased tumour invasiveness and adhesiveness to 
extracellular proteins, perhaps by the alteration of cellular dynamics, including increased 
MMP-2 expression and decreased e-cadherin expression 196. Rat intestinal epithelial cells with 
stable overexpression of COX-2 show several altered characteristics including increased 
adhesion to extracellular matrix 197. COX-2 inhibitors have been shown to decrease cell 
migration, cell adhesion, and tumour invasiveness in vitro and in vivo studies 192.  
Transcriptional regulation of COX-2 expression 
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Overexpression of COX-2 appears to be a consequence of both increased transcription and 
enhanced mRNA stability 198. Lipopolysaccharide (LPS) was the first inducer of COX-2 
expression to be identified 199. It is now known that most pro-inflammatory mediators 
stimulate COX-2 transcription via different signaling 198, including: growth factors, such as 
IGF, TGF and EGF 181; nitric oxide (NO) and reactive oxygen species (ROS) 200; and several 
pro-inflammatory cytokines such as IL-1 or IFN- 201. COX-2 protein levels are also regulated 
at a prost-transcriptional level via modulation of the stability of its mRNA. Signals from 
cytokines such as IL-1 and TNF- affect COX-2 mRNA stability. Hypoxia represents 
another regulator of COX-2 mRNA. It increases its stability most likely via induction of TNF-
 202 (Table 4).  
Table 4: Regulators of COX-2 expression  
Increased Expression (up-regulators) Decreased Expression (down-regulators) 
LPS p53 
Interleukin-1 Fish oil 
Interleukin-6 Estrogens 
Epidermal growth factor Glycogen synthase kinase 3 
Transforming growth factor- Glucocorticoids 
Tumor necrosis factor-  
Ultraviolet B  
Benzopyrene  
Androgens  
Inducible NO synthase  
reactive oxygen species (ROs)   
Wnt 
ras 
src 
Nuclear factor-B  
cAMP-ERP   
Data from E. Fosslien 187, Turini 203 and Pruthi 171
Glycogen synthase kinase 3 (GSK3) and glucocorticoids represent the most important 
negative regulator of COX-2 transcription. They achieve this effect via inhibition of NF-B 
204. Wild-type p53 markedly suppressed transcription of COX-2 205.  
NF-B is a crucial positive regulator of COX-2. NF-B is activated in response to a wide 
variety of stimuli, such as LPS. A growing body of evidence indicates that NF-B plays a 
central role in general inflammatory as well as immune responses. The promoter region of 
COX-2 contains two putative NF-B binding sites. NF-B has been shown to be a positive 
regulator of COX-2 expression in murine macrophages and human colon adenocarcinoma cell 
lines exposed to LPS 206,207 (Table 4). 
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CCAAT/enhancer Binding Protein Transcription Factors and COX-2 Regulation
The CCAAT/enhancer binding proteins (C/EBPs) are members of the basic region – leucine 
zipper (bZIP) class of transcription factors and play important roles in fundamental cellular 
processes including proliferation, growth arrest, and differentiation in a cell-type specific 
manner. There is a C/EBP binding site on the human COX-2 promoter region and C/EBPs are 
involved in regulating the activity of the COX-2 promoter 208. 
The functions of C/EBPs in the regulation of COX-2 transcription are cell type- specific and 
differentiation stage-specific. Even the same C/EBP isoform displays opposite effects 
depending on the cell type 208-210. C/EBP is known to be involved in the regulation of cell 
proliferation and differentiation. C/EBP can induce growth arrest in various cell types, for 
example, inhibits hepatocyte proliferation and also suppresses colony growth in mouse 
fibroblasts 211. Unlike C/EBP, C/EBP transcription factor has been shown to play a pivotal 
role in regulating key biological processes, such as cell proliferation, differentiation, and 
apoptosis, which are thought to be crucial in tumourigenesis 208. In mammary epithelial cells 
and hepatocytes primed by the agents causing acute phase response, C/EBP was 
predominantly expressed, whereas the level of C/EBP was quite low 212. A few experimental 
data have shown that C/EBP and NF-B are the most dynamical transactivators for COX-2 
promoter activation by diverse pro-inflammatory mediators 213. The transfection with C/EBP
led to increased COX-2 expression in gastric cancer cell lines 214,215. In human tumour, for 
instance, in gastric carcinoma, a positive relationship between the expression of C/EBP and 
COX-2 has also been reported 216.  
COX-2 Expression in Prostate Cancer 
Epidemiology 
The potential role of COX-2 in PCa has received considerable attention in the last several 
years. As in colon cancer, initial suspicion of the potential role of COX-2 in PCa came in the 
form of epidemiological evidence. Roberts et al. 217 observed in their cohort of 1,362 patients 
that the daily use of nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin, 
resulted in lower relative odds of PCa 217. Nelson and Harris noted a decreased relative risk in 
patients on over-the-counter and prescription NSAIDs 218. Interestingly of patients diagnosed 
with PCa those on NSAIDs were noted to be at somewhat lower risk for advanced cancer than 
age matched controls 219. In a recent meta-analysis of 12 published series evaluating NSAID 
use and PCa risk, Mahmud et al. 220 demonstrated that NSAID users have a lower relative risk 
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of PCa development than do nonusers. Patients with a diagnosis of PCa, those who took 
NSAIDs were noted to have a lower risk (risk ratio 0.73) of developing “advanced” PCa 
compared with age-matched controls 219. These findings were recently corroborated by a large 
cohort questionnaire study that examined the association between NSAID use and PCa 
incidence among 70,144 men 221. The results demonstrated that regular NSAID users had an 
18% lower overall risk of PCa and a 33% reduced risk of advanced disease 221. However, 
Langman et al. were unable to identify such a correlation in their British cohort 222. 
COX-2 mRNA and protein expression in prostate tissues 
In addition to these epidemiological observations, molecular and immunohistochemical 
studies have demonstrated that COX-2 overexpressed in human PCa.  
O’Neill and Ford-Hutchinson 223 firstly analyzed COX-1 and COX-2 mRNA expression in 
various human issues and found the highest levels were detected in the prostate where COX-1 
and COX-2 transcripts were present in approximately equal levels 223. Kirschenbaum et al.168
investigated the COX-1 and COX-2 in the human fetal and adult male reproductive tracts. 
COX-2 was strongly expressed in epithelial cells of both fetal and adult seminal vesicles and 
ejaculatory ducts. No COX-2 was found in the fetal prostate. In BPH samples, COX-2 was 
strongly expressed in smooth muscle cells.  
Evidence that increased COX-2 levels may be important in PCa development comes from 
preliminary results in human and canine prostates 163, 167, 224. Gupta et al. 163 reported that 
COX-2 mRNA level were 3.4-fold higher in PCa tissue compared with the paired benign 
tissue 163. Madaan 167 reported that COX-2 expression in the PCa was significantly different 
from those in BPH and were increased with increasing tumour grade. In contrast, only weak 
to moderate COX-1 expression found in tumour cells and its expression did not correlate with 
tumour grade. Several studies have similarly noted that human PCa overexpresses COX-2 
mRNA and protein compared with benign epithelium, as measured by immunohistochemistry, 
quantitative RT-PCR, and Western blot analysis 163-171. A few reports have shown that COX-2 
expression correlates with PCa stage, grade and progression 163, 164, 166-169. COX-2 expression 
is also increased in PCa lymph node metastasis 163, 164, 166-168, suggesting that in the prostate 
COX-2 may act in tumor promotion and progression 165, 171. Cohen et al. 225 reported that
COX-2 expression is an independent predictor of prostate cancer progression following 
radical prostatectomy. Hormonal therapy may induce the COX-2 expression in PCa as well, 
since one study found that neoadjuvant hormonal therapy induced the expression of COX-2 
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protein in PCa cells 226. COX-2 expression in the epithelial cells of HGPIN to a variable 
degree was also reported 165, 166, 168, 169.  
However, although most such studies have demonstrated increased COX-2 expression in the 
prostatic epithelial cells, some investigators have attributed the increased COX-2 expression 
to the accompanying inflammatory cells found in the neoplastic tissue and not from the cancer 
cells themselves 227. They found that the expression of COX-2 was not elevated in HGPN or 
in established PCa. In limited cases, when staining for COX-2 was observed in PCa, the 
extent of positive staining did not correlate with established clinical and/or pathological risk 
factors-Gleason score or pathological stage. By contrast to the neoplastic tissue, the consistent 
expression of COX-2 protein in PIA lesions was present 227.  
COX-2 expression in prostate cell lines 
In addition to immunohistochemistry and mRNA studies correlating COX-2 expression with 
PCa presence and behaviour, an increasing number of in vitro pharmacological studies have 
likewise implicated COX-2 expression in PCa progression. In PCa cell lines, COX-2 is 
expressed in androgen responsive (LNCaP) and androgen resistant (PC-3) cell lines 228-230. 
Furthermore, exposure of these cell lines to COX-2 inhibitors results in apoptosis induction in 
LNCaP and PC-3 cells in a time and dose dependent manner 184, 228-231. While COX-2 
inhibitors could suppress the proliferation of LNCaP and PC-3 cells, PrSC cells (stromal cells) 
were not affected by COX-2 inhibition 231. TNF is a strong inducer of COX-2 expression. It 
induced the COX-2 expression both in prostate epithelial cells and stromal cells 232.  
Tjandrawinata et al. provided evidence that increased PG synthesis has both growth-
promoting and positive feedback effects in PC-3 cells. The study suggested that the increased 
expression of COX-2/PGE2 contributes to prostate cancer development and this positive 
feedback activity of PGE2 may be responsible for the existence of COX-2 in these cells as 
compared to the short-life of the inducible COX-2 in other cells 233. 
In COX-2 cDNA transfected LNCaP cells (LNCaP-COX-2), the level of COX-2 mRNA and 
protein and the COX activity was significantly increased. Both cell proliferation in vitro and 
tumour growth rate in vivo were increased.  LNCaP-COX-2 cells also had increased secretion 
of VEGF protein, suggesting that the contribution of COX-2 on PCa progression was partly 
through increased VEGF 184. Another study showed that PC-3 high invasive cells produce 
higher PGE2 than PC-3 low invasive cells and PGE2 may enhance the cell invasion of the 
invasive cells234. Indomethacin, a non-specific COX inhibitor, and NS-398, a specific COX-2 
inhibitor, both inihibited the prostaglandin synthesis and cell invasion 234.  
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Treatment strategies based upon novel molecular targets in inflammatory 
pathways  
New treatment strategies based upon novel molecular targets in inflammatory pathways have 
been suggested and are currently being evaluated in experimental and clinical trials. 
Inflammatory components targeted by these therapies include agents that inhibit or block 
cytokines, NF-B activity, oxidative damage, or COX-2 (Fig 3) 90, 235.
Fig 3. Possibilities for prevention of prostate cancer. Data from Yegnasubramanian 236, Pruthi237, and Lu 121.  
TNF blockade 
Two TNF antagonists (etanercept, and infliximab) have been licensed for clinical trial in the 
treatment of rheumatoid arthritis and Crohn’s disease 238. There is clinical evidence for these 
actions of the anti-TNF antibody in rheumatoid arthritis joint tissue: inhibition of 
cytokine/chemokine production, reduced angiogenesis, prevention of leukocyte infiltration, 
inhibition of matrix metalloproteases, and improvement of bone-marrow function. All these 
actions would be useful in a biological therapy for cancer.
  
IL-6 antagonism
Monoclonal antibody to IL-6 was given to patients with myeloma. There was evidence of 
biological effect: deceased C-reactive protein, lower IL-6 production, and resolution of low-
grade fever 239. 
Anti-cytokines
A new generation of vaccines directed against cytokine activity could be beneficial in the 
treatment of cancer 240. These new vaccines could be targeted to agents that directly stimulate 
tumour cell growth, such as TGF- or IL-10, or could remove inappropriate suppression of 
immunefunction by aberrantly expressed cytokines. Clinical trials using vaccines directed 
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against EGF and VEGF in cancer patients have shown some potentially encouraging results. 
Further studies directed at cytokines and inflammatory pathways may further improve the 
potential benefit of these vaccines.  
  
NF-B inhibition
Therapeutic options directed at inhibiting NF-B function could possible reduce inflammation 
and subsequent repair processes. Salicylates and corticosteroids are known to inhibit NF-B 
function 241, but their effects are non-specific. A number of different agents have been 
developed that directly inhibit NF-B activation by blocking proteasomes, inhibiting normal 
NF-B activation pathways, or blocking NF-B transcription. Anti-oxidants have also been 
used as NF-B inhibitor, since ROS are known to activate NF-B.  
Anti-oxidants 
The potential role for anti-oxidants is very appealing. Intake of fresh fruit and vegetables 
appears to be inversely correlated with cancer of the esophagus, stomach, and pancreas 242,
although the specific factors involved remain undefined. A potential protective effect of 
specific vegetable components, suggested by a reduction of urinary ROS excretion, might be 
due to phytochemicals that induce enzymes scavenging electrophiles.  
• Selenium: Epidemiology studies have correlated low selenium with an increased risk of PCa 243-245. 
In addition, a clinical trial of selenium supplementation for the prevention of recurrent 
nonmelanoma skin cancer revealed a decrease in incident PCa, especially in men with low 
selenium at trial entry 246.  
• Vitamin E: Inverse correlations between vitamin E (-tocopherol and –tocopherol) and PCa 
risk have also been reported 247. A randomized clinical trial of -tocopherol and  carotene 
supplementation for the prevention of lung cancer in male smokers showed a 32% decrease in PCa 
incidence and a 41% decrease in PCa mortality in men who received -tocopherol 248.  
• Lycopene: Lycopene is a carotenoid that is found in a variety of foods, including watermelon and 
tomato, and it has been found in epidemiological studies to be associated with a lower risk of PCa 
29, 249. Consumption of vegetables containing the carotenoid lycopene and high lycopene blood 
levels have been associated with low PCa risk 250. A clinical trial in which men were fed tomato 
based pasta showed a decrease in oxidative genome damage in the prostate 251.  
• Sulforaphane: Consumption of cruciferous vegetables containing isothiocyanates, such as the 
chemoprotective compound sulforaphane, has been reported to reduce PCa risk 27. Preclinical data 
suggest that this micronutrient may decrease the risk of PCa 252. Sulforaphane can act as an 
antioxidant by inducing a plethora of carcinogen detoxification enzymes via a mechanism 
involving the cysteine rich protein Keap1 and the transcription factor Nrf2 253.  
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NSAIDs and COX-2 inhibitors in prostate cancer  
NSAIDs have been available during the past century for their analgesic and antiinflammatory 
properties. However, it was not until 1971, that Vane JR demonstrated that the anti-
inflammatory effects of NSAIDs occurred through inhibition of the COX enzyme 254.  
Typical NSAIDs (eg, aspirin, ibuprofen) function to nonselectively inhibit both isoforms of 
COX. It is through COX-2-specific inhibition that the antiinflammatory and analgesic 
properties of such medications occur. However, it is the nonselective inhibition of COX-1 that 
produces the well-known side effects of NSAIDs, including gastrointestinal irritation, 
impairment in renal blood flow, and reduced hemostasis 255. 
The discovery of the two different COX isoforms and their unique physiologic properties led 
to the intensive search for drugs to selectively inhibit COX-2 alone - a drug that can achieve 
the antiinflammatory effects of COX-2 inhibition without the toxicities that can result from 
COX-1 inhibition. Such selective COX inhibitors (COXIBs) have since entered mainstream 
medical practice, with approval by the Food and Drug Administration (FDA) of celecoxib in 
1998 and rofecoxib in 1999.  
Celecoxib appeared to be the most effective NSAID at clinically relevant concentrations 
against human prostate carcinoma cells in vitro 256. In vivo studies demonstrated a dramatic 
antitumour effect of selective COX-2 inhibition in nude mice models which injected with PC-
3 cells 228. This effect occurred via a combination of tumour cell apoptosis induction and 
down-regulation of tumour VEGF. In another animal study, celecoxib suppressed progression 
in the transgenic adenocarcinoma of the mouse prostate model 178.  
Potential Clinical Uses of COX-2 Inhibitors: Celecoxib has been evaluated in patients with 
biochemical progression after definitive therapy with beneficial effects 257. This study 
demonstrated a consistent, inhibitory effect on PSA progression in an androgen-independent 
fashion 257. The results suggest that COXIBs may help delay or prevent disease progression 
after biochemical failure and, perhaps, prolong the time until institution of androgen-
deprivation therapy.  
Perhaps the most important is the potential role of COXIBs in the treatment of hormone-
refractory disease. Preclinical studies have suggested an androgen-independent mechanism 
for the antitumour action of COXIBs in PCa 228. Investigators have shown that inhibition of 
COX-2 may work synergistically with certain chemotherapeutic drugs (eg, docetaxel) to 
inhibit growth in hormone-refractory xenografts 258. 
COXIBs may also play a role as a radiosensitizer in PCa. Wen et al. 259  demonstrated that the 
COX-2 inhibitors enhanced the antitumour effect of radiation in vitro and in vivo in PCa. 
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Another potential application of COXIBs is for bone metastases. A recent investigation has 
demonstrated that COX-2 is overexpressed in a mouse model of metastatic breast cancer and 
that COX-2-derived PGs may contribute to bone osteolysis 260. Correspondingly, 
administration of NSAIDs inhibited osteolysis due to bone metastases. In a sarcoma-based 
model of metastatic disease, selective inhibition of COX-2 decreased cancer pain, bone 
destruction, and even tumour growth 260. These provocative results warrant further study in 
bone metastases from PCa. 
COX-2 inhibitors in PIN: COX-2 inhibitors were also used for reducing the PIN number in 
transgenic mouse prostate model (TRAMP), which exhibits many similarities to human PCa. 
The results showed that the effectiveness of celecoxib and exisulind in reducing the PIN 
lesions by modulating a cascade of molecular targets involved in COX-2-dependent and -
independent mechanisms 177. 
COX-2 inhibitors have cardiovascular side effects: Although COXIBs offer efficacy while 
minimizing the unwanted side effects that are attributable to COX-1 inhibition, e.g. gastric 
ulceration, COXIBs may invariably cause an imbalance between PGI2 and thromboxane (TX), 
thus indicating that multiple and opposing cardiovascular influences may be operative during 
COX-2 inhibition. McGettigan and Henry performed a meta-analysis of controlled 
observational studies, which including 23 case- or cohort-controlled population studies, to 
compare the cardiovascular risks associated with COXIBs and other NSAIDs. The results 
showed that COXIBs (celecoxib and rofecoxib) have a lower safety profile than NSAIDs 
(naproxen and ibuprofen) 261. 
Precursor Lesions of Prostate Cancer 
Definition of prostate cancer precursor lesions 
The development of a solid tumour is generally thought to be a multistep process, whereby 
successive genetic events occur in a normal cell to render it increasingly malignant. The 
prototype for this model of carcinogenesis in solid tumours is colon cancer, but similar studies 
have confirmed this model in other diseases including breast and cervical cancers. In PCa, the 
genetic and epigenetic phenomena that are occurring in cancer development are not well 
understood, but there is evidence that premalignant lesions in the prostate may precede the 
development of cancer by many years.  
There are several criteria that should be met in order to consider a prostatic lesion as 
premalignant262: an epidemiological relationship must be revealed, the precursor lesion should 
be present at an earlier age than the cancer, and clear morphological ( for example, cellular, 
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histological, architectural ) similarities should be present. Also, premalignant lesions should 
be close to their presumed malignant equivalents. 
  
HGPIN 
In 1965, McNeal described lesions with possible premalignant features in prostatic epithelium 
263. In 1986, McNeal and Bostwick described the first criteria for the diagnosis of “intraductal 
neoplasia” 264. In 1987, Bostwick and Brawer introduced the term PIN - prostatic intra-
epithelial neoplasia 9. At the beginning, PIN was categorized into three grades with regard to 
architectural and cytological characteristics, taking into account that the alterations cover a 
continuum. In 1989, the classification was altered to low-grade PIN (LGPIN) and high-grade 
PIN (HGPIN), respectively 265. 
Morphologically, there are four basic patterns of HGPIN: flat, tufting, micropapillary, and
cribriform 266. These patterns often merge with each other. Other than diagnostic utility, these 
architectural patterns have no known clinical significance.  
Several studies indicate that HGPIN is the most likely precursor lesion of PCa 267-270, because 
of the similarities between them: 
1) Age. The frequency and extent of HGPIN lesions increase with age, and this increase is similar to 
the increase in diagnosis of PCa with age 271. 
2) HGPIN is found significantly more frequently in prostates with cancer 264. 
3) Coexistence. HGPIN often coexist with PCa in the same samples 267.  
4) HGPIN is predominantly located in the peripheral zone, the zone in which most clinically 
important prostate tumours are found 271. 
5) Morphological similarities. HGPIN is characterized by cellular crowding and stratification. There 
is inequality in cell and nuclear size. Hyperchromatism is frequently seen with an enlarged nucleus, 
often containing prominent nucleoli lines. These changes are also seen in Gleason grade 1-4 PCa 
272.
6) Histologically, the atypia observed in HGPIN is virtually indistinguishable from that of PCa 
except that in HGPIN the basal membrane is still intact 273. As HGPIN progresses, the likelihood 
of basal cell layer disruption increases. In HGPIN, the basal cell layer is disrupted or fragmented 
as demonstrated by 34E12. In PCa, there is complete loss of the basal cell layer. 
7) Both in HGPIN and PCa, collagenase type IV expression is increased as compared with normal 
prostate epithelium. This enzyme is responsible for basal membrane degradation and thus 
facilitates invasion 10, 274.
8) HGPIN and PCa share several nuclear properties, such as amount of DNA, chromatin texture, 
chromatin distribution, nuclear perimeter, diameter, and nuclear abnormalities 275. 
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9) Molecular and genetic similarities. Molecular abnormalities in HGPIN are mostly intermediate 
between benign gland and cancer, reflecting an impairment of cell-differentiation and regulatory 
control 276. Several genetic changes encountered in PCa cells can be found in HGPIN 275. Allelic 
loss is common in HGPIN and PCa 273. The frequent 8p12-21 allelic loss commonly found in PCa 
is also found in microdissected HGPIN. Other examples of genetic changes found in PCa already 
existing in PIN include loss of heterozygosity at 8p22, 12pter-p12, and 10q11.2, and gain of 
chromosomes 7, 8, 10, and 12. Alterations in oncogene Bcl-2 expression and replication error 
(RER+) phenotype are similar for HGPIN and PCa 277.  
10) PCa and HGPIN have similar proliferative and apoptotic indices 278. Mitotic figures and apoptotic 
bodies increase progressively from nodular hyperplasia to HGPIN 278. Greater cytoplasmic 
expression of Bcl-2 is observed in HGPIN and PCa than in benign and hyperplastic epithelium 273.  
11) Neovascularization is greater in HGPIN and PCa than in normal prostate. The available data 
indicate that angiogenesis has an important role in the progression of prostate neoplasia 279.  
Atypical adenomatous hyperplasia (AAH)  
Apart from HGPIN, several morphological lesions or conditions have been proposed that may 
act as potential precursor lesions of PCa. These are the morphologically distinct entities of 
atypical adenomatous hyperplasia (AAH), low grade PIN (LGPIN), and focal atrophy 269. 
AAH is a lesion characterized by a proliferation of small acinar structures that mimics 
adenocarcinoma because of histological similarities280. AAH appeared from 0.8% in needle 
biopsy specimens to 7.3% in TURP specimens without cancer 281.  AAH is most often located 
in the transition zone of the prostate in intimate association with BPH 282. It can also be found 
near the apex and in the periurethral area 10, 274. In AAH, the basal cell layer is discontinuous 
and fragmented on 34E12 cytokeratin immunostaining283. AAH is often associated with low-
grade adenocarcinoma arising in the transition zone 284, since there are morphological 
similarities. Cytogenetic analyses have detected abnormalities of chromosome 8 in very small 
proportions (4 - 7%) of AAH cases 282, 283.  
LGPIN  
LGPIN is quite difficult to recognize, as it has common features with normal and hyperplastic 
epithelium. It has the similar morphology as HGPIN, but most of the cells lacked prominent 
nucleoli. The nuclei are enlarged, vary in size, have normal or slightly increased chromatin 
content, and possess small or inconspicuous nucleoli. More prominent nucleoli, when 
observable, comprise less than 10% of dysplastic cells 267, 285. The basal cell layer normally 
surrounding secretory cells of ducts and acini remains intact 269, 270. The distinction between 
HGPIN and LGPIN is based primarily on the extent of cytological abnormalities (that is, 
43
prominence of the nucleoli) and secondarily on the degree of architectural complexity 286, 287. 
Immunostaining studies of microvessel density may help to differentiate HGPIN from LGPIN 
279.  
Prostatic Atrophy  
Atrophy in prostate related to aging and presumably attributed to androgen withdrawal is a 
consistent finding only in patients over the age of 70. There is no explanation for the great 
variation in the rate of involution seen among individuals below 70, but severe debilitating 
disease may produce advanced atrophy even in young men 2, 288.  
Classification of Prostatic Atrophy 
Atrophy of the prostate is identified as a reduction in the volume of preexisting glands and 
stroma and can be divided into two major patterns: diffuse and focal.  
Atrophy due to aging is characteristically diffuse. In its advanced stage, reduced secretory cell 
volume is usually accompanied by markedly reduced or absent staining for PSA and PAP. 
Diffuse atrophy can also result from a decrease in circulating androgens, most commonly 
produced by ‘‘total androgen blockade,’’ which consists of orchiectomy combined with 
antiandrogens, or luteinizing hormone-releasing hormone agonists combined with 
antiandrogens. This hormonal type of atrophy involves the prostate in a relatively uniform 
manner and shows unique histological features 289, 290.  
Focal atrophy lesions, by contrast, occur as heterogeneous patches, and contain a 
nonprominent basal cell layer, often attenuated. Although the term “focal” is used to indicate 
that these atrophic areas are limited to specific patches or ‘‘foci,’’ at times these patterns of 
atrophy may encompass very large areas of the prostate, especially in the peripheral zone. 
The biological significance of prostatic atrophy has been an area of interest since at least the 
1930s.  Franks 291 indicated that focal atrophy occurs chiefly in the ‘‘outer’’ portion of the 
prostate, now referred to as the ‘‘peripheral zone’’, and that it increases with advancing age.  
There are several morphological variants of focal prostate atrophy. These were first classified 
in detail by Franks who described four main patterns 291: 1, simple atrophy (SA) with/without 
cyst formation; 2, sclerosing atrophy; 3, post-atrophic hyperplasia (PAH): 3.a, lobular 
hyperplasia; 3.b, sclerosing atrophy with hyperplasia (post-sclerotic hyperplasia); and 4, 
secondary hyperplasia.  
McNeal et al. 2  found that almost all the focal atrophy were consequences of previous 
inflammation. They classified the focal atrophy into two groups: 1), postinflammatroy atrophy, 
2), cystic atrophy.  
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In more contemporary literature, several descriptions of various morphological patterns of 
focal prostate atrophy have been presented. To simplify the classification of these lesions, 
Ruska et al. 292 referred to most of them as SA or PAH. They defined the PAH lesions as the 
crowded focus of small atrophic acini. PAH contained more frequent prominent nucleoli and 
had the highest MIB-1 label index, higher than that in simple SA and benign nonatrophic 
glands. 
Proliferative inflammatory atrophy (PIA) 
De Marzo 293(1999) proposed the term PIA to designate discrete foci of proliferative glandular 
epithelium with the morphological appearance of SA and/or PAH, occurring in association 
with inflammation. The key features of PIA are: the presence of two distinct cell layers; 
mononuclear and/or polymorphonuclear inflammatory cells in both the epithelial and stromal 
compartments; and stromal atrophy with variable amounts of fibrosis. 
In 2006, a new classification was proposed 294: most focal atrophy lesions could be sub-
classified into the following four distinct subtypes: (i) SA, (ii) SA with cyst formation, (iii) 
PAH, and (iv) partial Atrophy. Apart from the definition of PIA, lesions in which the same 
prostate atrophy patterns do not contain increased inflammation were referred to as 
"proliferative atrophy" (PA). A more recent study showed that PIA is a more frequent finding 
in prostate with carcinoma and the simple atrophy was the most common type of PIA 295.  
PIA as a Precursor to HGPIN and Prostate Cancer 
Fig 4. Data from De Marzo et al 38
In 2003, Nelson et al. 131 proposed a model of the transition between PIA to HGPIN and 
prostate cancer. In 2007, De Marzo et al. 38 fulfiled the hypothesis of “injury and 
regeneration”. The morphological process was assumed to start from the initiated stage of the 
“stem cell”, then to intermediate cell differentiation, and at last, to the development of HGPIN 
or prostate cancer (Fig 4) 38. This hypothesis is mainly based on the evidences from 
morphological, cellular, and molecular studies. 
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Proliferation index in PIA 
Cell proliferation is a fundamental aspect in a number of prostatic diseases ranging from 
hyperplasia to neoplasia and can be studied using antibodies directed against nuclear antigens 
expressed in certain phases of the proliferation cycle, such as Ki-67 and PCNA.  
Feneley et al. 296 found the proliferation index of benign acini is consistently lower (0.19-
4.0%) than that of malignant acini (1.6-16%). They found that atrophic lobules showed a high 
proliferation index. Ruska et al. 292 studied the cellular kinetics in prostate needle biopsy 
specimens. Both SA and PAH had higher proliferation ratios and lower apoptosis than the 
nonatrophic glands. PAH lesions have the highest proliferation ratio and lowest apoptosis 292. 
De Marzo 293 noted that in PIA lesions, both basal and secretory-type cells showed an 
elevated Ki-67 staining index. Shah et al. 297 concluded that there was a significant increase in 
nuclear proliferation from normal prostate along a continuum: benign < SA < PAH < HGPIN 
< PCa (P < 0.001).  
Morphological transition between PIA, PIN, and PCa 
Franks considered a specific subtype of PAH (sclerotic atrophy with hyperplasia) as a putative 
neoplastic precursor given its close association with PCa 291. Liavag 298 demonstrated a similar 
topographical association between PAH and PCa. Several recent studies have re-examined the 
role of PAH as a potential neoplastic precursor. Shah et al.297 noted that SA and PAH were 
both frequently found and topographically located near or adjacent to PCa in the peripheral 
zone of the prostate gland. Two other studies examining the topographic location of PAH with 
respect to PCa concluded that PAH is extremely common in the periphery of the prostate 
gland. Putzi and De Marzo 299 identified the two-dimensional topographical relation between 
PIA and PCa. It was described as merging when the neoplastic-appearing epithelium of the 
HGPIN or carcinoma merged directly with PIA within a given acinus or duct. In a study with 
radical prostatectomies, morphological transitions between HGPIN and PIA frequently occur: 
42.5% of the HGPIN lesions were merged with PIA. Carcinoma did not merge with PIA. 
Another more recent study 300 reported that PIA lesions appeared to be directly merging with 
small foci of adenocarcinoma. Twenty five percent of the PIA lesions were found to merge 
directly with HGPIN and 31.3% of the PIA lesions contained at least some cells with 
prominent nucleoli (low-grade PIN). This finding supports a model in which the proliferative 
epithelium in PIA may progress to HGPIN. 
However, it should be noted that not all the pathologists have noted morphologic transition of 
PIA, HGPIN, and invasive adenocarcinoma 301-305 and that not all HGPIN or small carcinoma 
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lesions are associated with atrophy. It is not clear how these parameters are interrelated and 
what intermediates are involved. At the WHO Consensus Conference in Stockholm, it was 
emphasized that no relationship between atrophy and prostate carcinoma or HGPIN has been 
proven 267.  
Phenotype of PIA  
Cell populations in PIA: Based on the expression of keratins, four cell populations can be 
discriminated in the human prostate epithelium. Basal cells express high levels of CK5, CK14, 
p63, and low levels of AR, PSA, CK8, and CK18. Luminal secretory cells lack p63, CK5, and 
CK14, but express high levels of CK8, CK18, AR, and PSA. Additionally, cells have been 
identified with a keratin phenotype intermediate between basal and luminal cells, which co-
express high levels of CK5 and CK18 (CK5/18) as well as hepatocyte growth factor receptor 
c-MET 306, 307.  
Many of the atrophic epithelial luminal cells in PIA are candidates for intermediate cells. van 
Leenders et al. 306 reported that all the atrophic luminal cells are strongly positive for CK8/18. 
About 40% of atrophic luminal cells in PIA lesions expressed CK5. c-MET positive staining 
was present in 44% luminal cell in PIA. The double-staining immunofluorescence also 
showed that luminal cells in PIA often co-expressed CK5 and Ki-67. The results suggested 
that cells phenotypically intermediate between basal and secretory are enriched in PIA lesions.  
GSTP1: GSTs are an important class of enzymes that protect cells against genome damage
mediated by oxidants and electrophiles from inflammation or dietary exposures. There are 
five major families of cytosolic GST isoenzymes. The most extensively studied GST in the 
human prostate is the pi-form of GST (GSTP1). In human prostate, GSTP1 is expressed in 
most basal cells in normal prostate 293, and was lost in HGPIN and PCa, which is associated 
with hypermethylation of the CpG island encompassing the GSTP1 promoter139, 308. 
Methylation changes at this site have been detected in up to 100% of PCa DNA specimens 139, 
308. This suggests that GSTP1 may serve as a “caretaker” gene 309, the decreased expression of 
which might render prostate cells vulnerable to malignant progression.  
In comparison with the increased expression in basal cells of normal prostate, GSTP1 is not 
usually expressed in normal secretory luminal cells. In contrast, many of the luminal epithelial 
cells in PIA lesions express increased level of GSTP1, although some do not 293. Nakayama et 
al. 300 hypothesize that some PIA cells may acquire GSTP1 CpG island hypermethylation 
leaving these cells vulnerable to progress to HGPIN and/or PCa. In a study of microdissected 
tissues, GSTP1 CpG island hypermethylation was not detected in normal epithelium or in 
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BPH, but was found in 6.3% of PIA lesions, in 68.8% of HGPIN lesions and in 90.9% of 
adenocarcinoma lesions. It is possible that increased expression of GSTP1 in PIA may result 
from the presence of an ongoing oxidative insult to this tissue, with silencing of GSTP1 
function related to the development of cancer 293.  
Chromosome 8p22 loss and 8 centromere (8c) gain: PIA and HGPIN also share some 
chromosomal changes. Both lesions had significantly higher percentages of chromosome 
8p22 loss than did normal prostate epithelia. Gain of centromere 8 (8c) was also detected in a 
few atrophic lesions 297, 310, 311.  
Bcl-2: In the benign prostate, Bcl-2 immunohistochemical staining was consistently observed 
in the basal layer in the ducts and acini, but was absent in luminal cells 44. In PCa, increased 
Bcl-2 protein levels are associated with high-grade tumours, advanced stage,  metastasis, and 
androgen-independent 312, 313. Baltaci et al. 277 reported detectable Bcl-2 in both LGPIN and 
HGPIN and its absence in normal and BPH prostate tissues. However, in the BPH glands 
within an area of prostatitis, both the basal and luminal cells expressed Bcl-2 indicating that 
inflammation was associated with Bcl-2 expression 314. An inverse relation between Bcl-2 and 
AR was found in many PIA glands 293. There was also a significant relation between Bcl-2 
expression and the type of lesion: PAH lesions show higher overall levels of Bcl-2 than 
lesions not containing PAH 293. 
P27kip1 belongs to the Cip/Kip family, and functions as an important cell cycle gatekeeper.
Down-regulation of p27Kip1 occurs in the vast majority of PCa and reduced levels correlate 
positively with Gleason grade 315, 316. Down-regulation of p27Kip1 was detected in HGPIN 317. 
The absence of p27Kip1 was also reported in PIA lesions 293, 306. 
COX-2: Zha et al.227 reported COX-2 overexpression in PIA lesions. In their study, COX-2 
was not elevated in HGPN or in established PCa. By contrast, there was consistent expression 
of COX-2 protein in PIA lesions.  
P53: Tumour suppressor gene p53 is the most commonly mutated gene in human cancers. In 
common with many other human cancers, p53 mutations are also seen in PCa with a wide 
range of 5-65% 318. 319. In PIN cases, p53 mutation was reported from 5% to 70% 320-324. The 
frequency of p53 mutations in microdissected PAH lesions was 5.3%, which was similar to 
that in HGPIN (4.2%) in the same report 325.  
c-MET: c-MET has been implicated in embryogenesis, tissue reorganisation, and tumour 
progression. c-MET is overexpressed in several human malignancies including prostate 
carcinoma 326-328.  The c-MET protein was detected in a substantial number of PCa and more 
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often in metastatic growths of prostate carcinoma and in androgen insensitive PCa cell lines 
329, 330. 
Interestingly, levels of c-MET are also raised in some inflammatory lesions, such as ulcerative
colitis and obstructive cholangiopathy 331. In these inflammatory lesions c-MET might be 
involved in cell proliferation, migration, and differentiation as part of a regenerative process. 
In agreement with the stem cell model of Isaacs and Coffey 332, increased expression of c-
MET together with their high proliferative activity supports the concept of intermediate cells 
as putative progenitor cells for prostate carcinogenesis. In a study by van Leenders GJ et al. 306, 
overexpression of c-MET was documented in PIA lesions and it was suggested that PIA is 
enriched with intermediate cells.
P63, a basal cell marker, is used as a tool to determine the state of the basal cell layer and to 
distinguish the regions of HGPIN from PCa 58. In PIA lesions, however, P63 negative and 
P63 positive staining were detected in both the luminal and basal cell layers 333. 
PSCA: Prostate stem cell antigen (PSCA) is a cell surface antigen expressed in normal 
prostate and associated with human and murine PCa. In normal prostate epithelial cells (PrEC), 
PSCA-positive cells were characterized by a more differentiated morphology and a slower 
proliferative rate than PSCA-negative cells, and expressed CD44, PSA, and AR, but lost 
expression of p63. PSCA may be a unique marker of an intermediate cells 334. 
P16/CDKN2, a cyclin-dependent kinase inhibitor, is frequently altered in prostate cancer 335. 
Increased expression of p16 was also reported in PIA lesions 336. 
AR down-regulation: AR was found to be down-regulated in PIA 293. Although the 
mechanism(s) for the loss of AR expression are not completely understood, it is possibly that 
the local inflammation and its inflammatory microenvironment, including the local high level 
of inflammatory cytokines, initiate a serious of molecular alterations in prostate atrophic 
epithelial cells, including AR down-regulation 88. Very few articles analyzed the down-
regulation of AR in non-malignant prostate epithelial cells.  Bonkhoff noticed that AR status 
and Bcl-2 showed inverse correlation 278.  In vivo studies suggested that inflammatory 
cytokines may play roles in down-regulate AR expression. AR mRNA and protein levels in 
the LNCaP cells could be down-regulated by EGF 86, basic fibroblast growth factor (bFGF) 87, 
and TNF 88. Moreover, IL-1 is also responsible for down-regulation of AR protein 
expression 89.  
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AIM OF THE STUDY
The main aim of the studies in this thesis was to investigate the association between chronic 
inflammation and the carcinogenesis of prostate cancer, with a specific focus on the role of 
the molecular variation of PIA lesions and the morphological transition between PIA lesions 
and the malignancies in human prostate samples.  
Specific aims of studies 
– To examine the expression of COX-2 in atrophic lesions and to investigate the 
correlation between COX-2 expression, the anti-apoptosis protein Bcl-2, and the 
proliferation state of prostatic epithelial cells, 
– To assess focal chronic inflammation densities and its association with COX-2 
expression in prostatic epithelial cells in PIA lesions, 
– To detect COX-2 expression in human prostate cancer tissues and to assess the 
microvessel density in prostate cancer tissues and the relation to COX-2 expression in 
tumor cells,  
– To elucidate the possible role of focal chronic inflammation in human prostate cancer 
tissues in inducing COX-2 overexpression, 
– To detect the expression of the transcription factor CCAAT/enhancer binding protein 
 (C/EBP) in PIA lesions and to investigate the association with COX-2 expression, 
focal chronic inflammation, and the epithelial cell proliferation state, 
– To elucidate the morphological transition among PIA, HGPIN, and prostate cancer in 
radical prostatectomy specimens and try to find useful markers to help to detect 
atrophic epithelial cell in malignancy areas.  
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MATERIALS AND METHODS  
Human Materials
Benign Prostatic Hyperplasia (BPH) specimens: Sixty-eight BPH specimens were obtained 
from the Department of Urology, Shandong Provincial Hospital, China. The patients’ ages 
varied between 51 and 82 years (median age 71). All of the tissues were fixed in formalin, 
embedded in paraffin. Serial sections were cut at 4-	m thickness.
Radical prostatectomy specimens: The material consisted of randomly chosen tissue 
samples obtained from radical prostatectomy specimens from 93 patients with prostate 
adenocarcinoma, including 78 cases from the Department of Urology, Sahlgrenska University 
Hospital, Göteborg, and 15 cases from Department of Pathology, Shandong Provincial 
Hospital, China. All the preoperative stages were T1c (n = 78) and T2a (n = 15). None of the 
patients had received prior hormone therapy, chemotherapy, or radiation therapy. The age 
range of the patients was between 52 and 78 years (median age, 65). Specimens were fixed in 
10% buffered formalin, embedded in paraffin.  
Histological Identification  
PIA: PIA lesions were classified into the following types: simple atrophy (SA), postatrophic 
hyperplasia (PAH), or mixed simple atrophy/postatrophic hyperplasia 291-293. The morphologic 
definitions of SA, PAH, and mixed SA/PAH were as below: 
SA: consists of atrophic cells lining acini of relatively normal calibre, having no papillary fronds, 
and where the number of glands per unit area does not appear to be increased relative to normal 
tissue. SA usually involves an entire lobule, although isolated acini may be affected. The acini are 
small and show a lower than normal height of the epithelial cells, and the surrounding stroma may 
or may not show fibrosis.  
PAH: consists of acini that are small and round and appear in a lobular distribution, often 
surrounding a somewhat dilated duct with an apparent increase in the number of small glands as 
compared with normal tissue. Fibrosis may or may not be present in the stroma. When present, the 
proliferation is irregular and can result in distortion of the acinar lumen. 
Mixed lesions: the above patterns are found in the same region, appearing to merge.  
PIN: The identification and classification of HGPIN are based mainly on the cytological 
characteristics of the cells 269, 274. HGPIN is composed of cells with histologic features of 
prostate adenocarcinoma occurring in pre-existing prostatic acini/ducts. Cells are 
characterised with large nuclei of relatively uniform size, increased chromatin content, which 
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might be irregularly distributed, and prominent nucleoli that are similar to those of carcinoma 
cells. The basal cell layer may have frequent disruptions. Four basic patterns of HGPIN, flat, 
tufting, micropapillary, and cribriform, were identified as described by Bostwick et al. 266.  
Lesions with similar morphology, but in which most of the cells lacked prominent nucleoli, 
were classified as LGPIN. The nuclei of cells composing LGPIN are enlarged, vary in size, 
have normal or slightly increased chromatin content, and possess small or inconspicuous 
nucleoli. 
PIA-merging HGPIN: The histological definition of PIA-merging HGPIN was any 
malignant cell with fraction within a single PIA lesion. The periglandular stroma in these 
lesions often showed mononuclear inflammatory infiltrates mainly composed of lymphocytes, 
macrophages, and occasionally plasma cells. At times, mononuclear cells were prominent 
both intraluminally and in the epithelium as well. 
PIA-merging adenocarcinoma (PIA-merging PCa): Any PIA lesion with a fraction of 
carcinoma was considered as PIA-merging PCa. Presence of adenocarcinoma was diagnosed 
according to the criteria of Mostofi and Price 337.  
Histopathological classification for chronic prostatic inflammation: The histopathological 
classification system  for chronic prostatic inflammation (Nickel et al.) 338 was used to classify 
prostatic inflammation into three grades of severity: mild, moderate, and severe, and three 
inflammation patterns: glandular, peri-glandular, and both peri-glandular and glandular (Table 
5) 
Table 5. The classification of prostatic inflammatory infiltrates (Nickel et al.). 
Feature Details 
Anatomical location Histological pattern 
glandular Inflammatory infiltrates lie within duct/gland epithelium and/or lumens. 
periglandular 
Inflammatory cells lie within prostatic stroma but not centred on prostatic 
glands/ducts and lie  50 µm from them. 
Extent Tissue area involved in inflammatory cell infiltrates 
focal < 10% 
multifocal 10–50% 
diffuse  > 50% 
Grade Morphological description (typical inflammatory cell density, cells/mm2) 
1/mild 
Individual inflammatory cells, most of which are separated by distinct intervening 
spaces (< 100). 
2/moderate 
Confluent sheets of inflammatory cells with no tissue destruction or lymphoid 
nodule/follicle formation (100–500). 
3/severe 
Confluent sheets of inflammatory cells with tissue destruction or nodule/follicle 
formation (> 500). 
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Antibodies 
The antibodies and conditions used in this study are indicated in Table 6. 
Table 6. Antibodies and conditions. 
Antibody Company Clone, code Dilution 
COX-2 Cayman Chemical Co. PAb, 160126 1:100 
COX-2* NeoMarkers Co. SP21 1:200 
COX-2 blocking peptide Cayman Chemical Co. 360106 10	g/ml 
COX-1 Cayman Chemical Co. PAb, 160110 1:50 
PCNA NeoMarkers Co. PC10 1:200 
AR NeoMarkers Co. Ab-1 1:50 – 1:100 
Ki-67 NeoMarkers Co. MB67 1:100 
Ki-67* NeoMarkers Co. SP6 1:100 
HMW keratin  DAKO Co. 34E12 1:200 
CK5 Abcam Ltd.  ab24647 1:200 
LMW keratin, CK8 NeoMarkers Co. 35 H11  1:200 
Bcl-2 NeoMarkers Co. Ab-1 1:100 
CD3 NeoMarkers Co. PS1 Ready to use 
CD3 Abcam Ltd.  PAb 1:25 
CD20 NeoMarkers Co. L26 Ready to use 
CD31 NeoMarkers Co. JC/70A 1:25 
CD68 NeoMarkers Co. KP1 Ready to use 
C/EBP  Sant Cruz Bio. H-7 1:200 
c-MET Santa Cruz Bio. C-28 1.500 
GSTP1  MBL PAb 1:4000 
p27 NeoMarkers Co. DCS-72.F6 1:200 
P53 Santa Cruz Bio. DO-1 1:100 
P53* NeoMarkers Co.  SP5 1:100 
p63 NeoMarkers Co. 4A4 1:100 
PSCA NeoMarkers Co. PAb 1:200 
Chromogranin A NeoMarkers Co. LK2H10 1:500 
*: Rabbit monoclonal antibody. PAb, polyclonal antibody.  
Immunohistochemistry (IHC)
IHC staining: Two immunohistochemistry systems were used in this study: ABC kit (Vector) 
and EnVision™ system (DAKO Co.).  
COX-2 IHC staining was performed using the ABC kit (Vector).  Briefly, sections were 
rinsed with methyl alcohol-hydrogen peroxide and then microwaved in citrate buffer (pH 6.0) 
to induce epitope retrieval.  Diluted COX-2 primary antibody (1:100) was incubated on slides 
at +4oC overnight and then incubated with biotinylated secondary antibody at room 
53
temperature. For localization, avidin-biotin complex was applied at room temperature for 30 
minutes followed by 3,3’-diaminobenzidine tetrahydrochloride (DAB) as the chromagen. 
Slides were counterstained with Mayer hematoxylin. 
  
As a negative control for nonspecific staining, COX-2 blocking peptide was added to the 
diluted COX-2 antibody at a final concentration of 10 μg/ml to the antibody mixture and 
incubated for 1 hour at room temperature before the application of the COX-2 antibody to the 
slides. Then manual IHC staining was performed as described above. 
  
Ki-67 IHC staining was performed with the EnVision™ system. Briefly, after microwaving in 
citrate buffer, the section was incubated with primary antibody at room temperature for 30 
min and then incubated with horseradish peroxidase (HRP) labelled polymer for 30 minutes at 
room temperature.  After washing with PBS buffered, DAB was used as the chromagen under 
the control by microscopy. Slides were then counterstained with Mayer hematoxylin.  
Double IHC staining: In order to accurately evaluate the expression of two reagents in situ, 
double IHC staining was performed with various combinations of antibodies. 
 To detect the COX-2 expression and its association with focal inflammation: COX-2/CD3, 
COX-2/CD20, and COX-2/CD68. 
 To detect the COX-2 expression on different epithelial cell layers: COX-2/34βE12 and COX-
2/CK8. 
 To evaluate the proliferation state: COX-2/Ki67 and COX-2/PCNA. 
 To assess the microvessel density and the local COX-2 expression: COX-2/CD31. 
DAKO EnVision Doublestain System (DAKO Co.) was used in this procedure. Briefly, 
serially consecutive sections at a thickness of 4 µm were treated for epitope retrieval as 
described above. After being incubated with peroxidase block for 5 minutes at room 
temperature, the slides were exposed to the first primary antibody (1:100) and incubated at 
+4oC overnight or 30 minutes at room temperature. The slides were then incubated with 
horseradish peroxidase (HRP) labeled polymer for 30 minutes at room temperature. The first 
antibodies immunostaining was labeled by applying DAB for 1-5 minutes. Next, Doublestain 
Block was added to the slides, 'and the slides were incubated for 3 minutes. Then the slides 
were incubated with the second primary antibody for 30 minutes at room temperature 
followed by application of alkaline phosphatase (AP) labeled polymer for another 30 minutes. 
The second substrate-chromagen solution, Fast Red, was incubated on the slides for 1-5 
minutes. Slides were counterstained with Mayer hematoxylin and cover slipped with DAKO 
Glycergel.   
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Evaluation of IHC staining:  
 COX-2 IHC staining: COX-2 positive staining was identified by the presence of marked diffuse 
brown (DAB) cytoplasm or perinuclear staining in prostate epithelial cells. If any portion of 
epithelia in a prostate gland showed immunoreactivity, then the gland was considered as COX-2 
positive stained. 
 HMW keratin 34E12 and CK8 both label the cytoplasm of epithelium. In normal prostatic 
acini and ducts, 34E12 only appears in the basal cell layer and CK8 in luminal cells. Similar to 
34E12, P63 also only appears in the basal cell layer, but it shows nuclear immunostain instead 
of cytoplasm. 
 CD3, CD20, and CD68 are all expressed in the cytoplasm staining.
 Ki-67 and PCNA are both the proliferation markers, and both show nuclear immunostaining.  
 C/EBP: C/EBP is only expressed in the nucleus.  
 AR and p27 are mainly expressed as in nuclear staining and occasionally in cytoplasm. Only 
nuclear staining was evaluated as positive.  
 Bcl-2, GSTP1, PSCA, and c-MET: cytoplasm IHC staining.   
Evaluation of double IHC staining: The two antigens staining in double IHC staining slides 
were identified by color: the first antigen was stained brown (DAB) and the second red (Fast 
Red). For example, in COX-2/CD3 double IHC staining slides, apart from the brown 
immunostaining of COX-2 on prostate epithelium, the T-lymphocytes were labeled with 
cytoplasm red staining. PCNA and Ki-67 immunostaining were identified by the nuclear red 
immunostaining. When only one cell coexisted both the cytoplasmic brown staining for COX-
2 and nuclear red staining for PCNA or Ki-67 were recorded as the PCNA or Ki-67 labelled 
COX-2 positive cell.  
Quantitation of IHC Staining  
 COX-2 IHC staining: Quantitation of COX-2 immunostaining was performed on 5 to 10 ocular 
measuring fields per slide chosen randomly, under a microscope at a power of x200. 
 Proliferation index: PCNA and Ki-67 label counting were performed by counting 10 to 20 
randomly selected microscopic fields at X400 magnification of each slide on COX-2/PCNA and 
COX-2/Ki-67 double IHC staining sections. The labeling index is the percentage of labeled cell 
nuclei over the total number of counted epithelial cell nuclei.  
 Bcl-2: In COX-2/Bcl-2 double IHC staining slides, Bcl-2 labeling was classified into two score 
groups based on the location of the Bcl-2 immunostaining in prostate epithelia: Bcl-2 score I: 
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only the basal cell layer of prostate epithelia stained with Bcl-2; Bcl-2 score II: not only the 
basal cell but also the luminal cell layer were detected with Bcl-2 immunostaining. Similar 
evaluation was also used for GSTP1 and c-MET immunostaining.
 CD3, CD20, and CD68 for chronic inflammation (paper I, II, III, and IV): In COX-2/CD3, 
/CD20, and /CD68 double staining slides, severity of inflammation grades was evaluated by 
counting inflammatory cells in the area around each gland within 50	m 338 .   
 C/EBP: In each case, 5 to 30 normal-appearing glands and 1-6 PIA lesions were selected at 
random to assess the IHC staining. If any portion of epithelia in a prostate gland showed 
C/EBP nuclear staining, then the gland was considered positive.  
 AR down-regulation: AR down-regulation was defined as when  1/3 luminal epithelial cells 
lost the AR nuclear staining or/and  2/3 luminal epithelial cells had weak AR nuclear staining 
in a single gland compared with the adjacent normal-appearing glands.  
 Microvessel density assessment: Any single endothelial cell or cluster of endothelial 
cells labeled with CD31 was regarded as a single microvessel. The quantification of 
microvessels was performed by counting 20 to 40 randomly selected microscopic fields 
of prostate cancer at 400 x magnification (high power fields, HPF) for each slide. The 
values of the second antigen staining were regarded as inflammatory cell density or 
MVD (/ HPF, 400 x). 
Immunofluorescence 
To determine whether the CK5 positive epithelial cells showed increased proliferative activity 
and decreased p27kip1 expression, double-staining immunofluorescence of Ki-67 and CK5, as 
well as p27Kip1 and K5 was performed. 
Statistics 
Statistical analysis was carried using SPSS for Windows software. The Pearson Chi-Square 
test was used to analyze the significance of COX-2 expression among various kinds, grades, 
and patterns of inflammation, and Bcl-2 expression (paper I). Chi-square test and/or Fisher 
exact test was also used to analyze the differences in C/EBP expression in relation to 
inflammation grades, COX-2 expression, and AR down-regulation (paper III) and in relation 
to the differences between proportions in paper IV. The Mann-Whitney U test was used for 
comparison of different groups, such as the significance of COX-2 expression, PCNA indices, 
and Ki-67 indices among different groups in atrophic lesions (paper I); COX-2 expression 
IHC score and the relationship with Gleason score, the inflammatory cell density, and MVD 
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(paper II), and the C/EBP expression ratio and the relationship with inflammatory cell 
density (paper III), and the comparison of HGPIN and PIA-merging HGPIN among groups 
(paper IV). Spearman rank correlation coefficient test was used to analyze the strength of 
association between the COX-2 IHC score and inflammatory cell density or MVD in paper II.  
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RESULTS AND DISCUSSION 
Over-expression of COX-2 in Prostate Atrophic Lesions of BPH Samples and the 
Relation to Proliferation Index and Association to Apoptosis (paper I) 
COX-2 over-expression and co-expression with CK8 in PIA 
The expression and function of COX-2 in prostate has been the subject of recent multiple 
reports. In general, COX-2 expression in normal prostate tissue is either weak or nonexistent, 
and prostate cancer tissue shows a marked overexpression of COX-2. The results in paper I 
show that COX-2 was overexpressed in the atrophic lesions, both in SA and PAH, in 
comparison with the low COX-2 level in normal prostatic acini/ducts. The double IHC 
staining of COX-2/34βE12 and COX-2/CK8 clearly showed that COX-2 was co-expressed 
with CK8, suggesting the luminal phenotype.   
These results were basically in line with other studies that COX-2 was seldom expressed in 
normal luminal epithelium. Only a few articles studying COX-2 expression in BPH were 
published and the results were contradictory. Furthermore, no consensus has been reached 
concerning which cell types express COX-2 in the prostate and at which stage of the disease 
this expression becomes elevated. Kirschenbaum et al.168 have made a systematic 
investigation of COX-2 expression in both fetal and adult male reproductive tracts, including 
normal prostate and BPH. In prostate, COX-2 was negative in fetal prostate, was strongly 
expressed in the smooth muscle cells and had no expression in the luminal epithelial cells 168. 
However, Madaan reported that COX-2 was constitutively expressed in the luminal cells of 
the BPH samples 167. In the present study, we found that COX-2 immunostaining mainly 
appeared in the atrophy glands (PIA lesions), suggesting that in comparison with the normal 
acini and ducts, the PIA lesions showed a different phenotype. This support the hypothesis 
that such atrophic cells are intermediate cells that have been identified between basal and 
luminal cells and that co-express both CK5 and CK8 as well as hepatocyte growth factor 
receptor c-MET, and lack p63 306. According to the stem cell hypothesis 339, these cells may 
develop into PIN or PCa.  
COX-2 expression and correlation to inflammation in BPH 
Another interesting point made in this study is that COX-2 expression was related to the focal 
chronic inflammation. COX-2 immunostaining was found closely adjacent to the focal 
chronic inflammation, both inside and surrounding the prostate foci. The predominant 
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inflammatory cells are T-lymphocytes and macrophages. These data indicate that focal 
chronic inflammation might play an important role in inducing COX-2 expression in BPH.  
BPH is one of the most common diseases in aging men. Nonetheless, the etiology of BPH is 
far from being completely understood, despite the major efforts made by molecular and 
clinical researchers. Most of the initial research studies focused on hormonal factors, 
considering that advanced age and the presence of functioning testes to be the two best-
established conditions for the development of BPH. There is emerging evidence that prostatic 
inflammation may contribute to prostate growth either in terms of BPH or neoplastic changes. 
The Medical Therapy of Prostatic Symptoms (MTOPS) study showed that men with 
inflammation had a significantly higher risk of BPH progression and acute urinary retention 
340. The use of COX-2 inhibitor in combination with a 5-alpha-reductase inhibitor could 
increase the apoptotic index in BPH tissue 340. Studies have also addressed the correlations 
between inflammation, apoptosis, and the development of prostate cancer 292, 293.
Inflammation is thought to incite carcinogenesis by causing cell and genome damage, 
promoting cellular turnover. In theory, an inflammatory microenvironment may be ideal for 
the development of tumours, owing to up-regulation of various mitogenic, anti-apoptotic and 
angiogenic factors. Increased levels of cytokines in response to inflammation may influence 
cell survival, growth and differentiation. COX-2 is up-regulated by certain mitogens, growth 
factors and cytokines. The potential chemopreventive effects of various anti-inflammatory 
agents, i.e. COX-2 inhibitors and NSAIDs, lend credence to these observations. The role of 
COX-2 in BPH has not been conclusive. However, this study clearly demonstrates that COX-
2 overexpression in BPH exists and is associated with a cascade of other events, including 
increased T-lymphocytes and macrophages. It remains unclear whether or not proinflamma-
tory cytokines induce COX-2 expression, and, if so, the clinical relevance. The role of 
inflammation in the pathogenesis of BPH and disease progression will be an exciting avenue 
of research in the near future. The exact cell biological mechanisms may provide novel 
therapeutic options in the treatment of both BPH and PCa.
COX-2 expression in PIA and the association with increased Bcl-2 level 
Both inflammation and apoptosis are of major interest in understanding the etiology of BPH. 
Bcl-2, an anti-apoptotic factor, is normally detected in the basal cell layer of the prostate 
glands, while no staining is present in luminal cells341. Bcl-2 expression, however, is observed 
in luminal cells in PIN and in prostate cancer, and  its overexpression has been linked to 
chronic inflammation 314. COX-2 overexpression and up-regulation of Bcl-2 are associated 
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with decreased apoptosis 197. Bcl-2 blocks apoptosis, an important step in the pathogenesis of 
prostate cancer, responsible for the decreased response to androgen ablation therapy in 
prostate tumours as compared with normal prostate tissue 44. Interestingly, treatment of 
LNCaP cells with a selective COX-2 inhibitor NS398 caused down-regulation of Bcl-2 
expression 230. It suggests that COX-2 might induce Bcl-2 expression.     
It is known that inflammation is involved in several kinds of cancers, including prostate. 
Specifically, free radicals, predominantly oxygen and nitrogen species, and growth factors are 
assumed to alter protein structure and function, causing lipid peroxidation and gene mutations. 
Pathological, experimental, and epidemiological data support those relationships. The 
increased level of Bcl-2 shows indirectly the anti-apoptosis in PIA cells. In fact, relevant 
pathological evidence has highlighted the role of PIA as a prostate cancer precursor. 
Moreover, a rat prostate model supplied strong evidence that pathogenesis of prostatic 
neoplasia proceeds from inflammation to PIA and then to HGPIN 38, 116.  Rats fed with 2-
Amino-1-methyl-6-phenylimidazo (4,5-b)pyridine (PhIP) showed significant prostate 
inflammation and atrophy and, HGPIN was also observed to develop directly from the 
atrophic epithelium 38, 116. 
Increased proliferation index in COX-2 positive staining PIA
Normally, luminal epithelial cells have a low proliferating index, as compared with the basal 
prostate cells, which was assumed to be the place where prostatic stem cells are located. 
However, in the present study, the COX-2 positive expressing luminal cells showed increased 
proliferating index, which labelled both for Ki-67 and PCNA. Glands with COX-2 positive 
staining had higher a PCNA label index than COX-2 negative glands, and the highest PCNA 
label index appeared in the COX-2 positive cells. Both PAH and SA lesions had higher 
PCNA and Ki-67 label indices than normal glands.  
COX-2 overexpression is assumed to induce the cellular proliferation in various cell lines via 
related prostaglandin (PG) production. Enhanced PG synthesis may contribute to 
carcinogenesis in several ways, including direct stimulation of cell growth. Both PGE1 and 
PGE2 stimulate proliferation of mammary epithelial cells in the presence of EGF 182, 183. 
Treatment of cells with a COX-2 inhibitor could reverse this phenotype 197.  
Overall, in the study of paper I, we conclude that COX-2 is expressed in benign prostate 
tissues, especially in atrophic lesions, and is associated with inflammatory cell infiltration. T-
lymphocytes and macrophages both appear to play important roles in inducing the luminal 
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prostate epithelial cells to express COX-2. These COX-2 positive staining epithelial cells have 
higher proliferation index and increased levels of Bcl-2. This observation, in combination 
with findings from other studies 342, 343, suggest that chronic inflammation and subsequent up-
regulation of COX-2 could be involved in the early pathogenesis of prostate disorders. These 
COX-2 positive expressing epithelial cells may possibly develop further, for instance, to PIN 
or prostate cancer, since these cells have both regeneration and anti-apoptosic phenotypes. It 
is therefore interesting to discuss why COX-2 is up-regulated and how this may influence 
cellular function in prostate epithelial cells. The COX-2 expression in prostate cancer, just as 
the chronic inflammation induced the COX-2 expression in BPH, remained the unanswered 
questions.  
COX-2 Expression in Malignant Prostate Tissues and the Relation to Gleason Score and 
Angiogenesis (Paper II) 
In a previous study we have shown that COX-2 is locally up-regulated in prostate atrophic 
lesions in BPH if T-lymphocytes and macrophages are present. Such COX-2 positive 
epithelial cells had increased levels of Bcl-2 and a higher proliferation index compared with 
COX-2 negative cells 344. In paper II, we tested the hypothesis that COX-2 is associated with 
local chronic inflammation in prostate cancer, and assessed the relationship between COX-2 
and the Gleason score for prostate cancer. In addition, we reported a new finding, that COX-2 
was related to angiogenesis in prostate cancer. This finding confirmed the hypothesis that 
COX-2 contributes to angiogenesis and would support further clinical assessment of anti-
angiogenesis therapy and COX-2 inhibitors, which have already shown promise in various 
trials 345. 
COX-2 expression in PCa and relation to Gleason score 
In this study, COX-2 positive staining tumour cells were detected in 40 of 43 cancer samples. 
The quantitative immunostaining data showed that the majority of cases (65%) had weak 
immunostaining of COX-2, while 28% had the intermediate or strong COX-2 expression. 
There was a significant association between elevated COX-2 expression and Gleason score: 
high Gleason score (> 7) patients had stronger COX-2 immunostaining  (P = 0.002). 
Our finding is generally in line with previous observations, which conclude that there is up-
regulation of COX-2 in prostate cancer. Furthermore, several studies have shown that COX-2 
expression correlated with disease stage, Gleason grade, and progression 163, 164, 166, 167, 346.
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Increased COX-2 expression was also seen in lymph node metastases 165, 171. COX-2 
expression has even been regarded as an independent prognostic indicator 225. 
However, although most such studies have demonstrated increased COX-2 expression in the 
prostatic epithelial cells, some investigators have attributed the increased COX-2 expression 
to the accompanying inflammatory cells found in the neoplastic tissue rather then from the 
cancer cells themselves 227. They found that the expression of COX-2 was not elevated in 
HGPN or in established PCa. In limited cases, when staining for COX-2 was observed in PCa, 
the extent of positive staining did not correlate with established clinical and/or pathological 
risk factors - Gleason score or pathological stage. In contrast to the neoplastic tissue, the 
consistent expression of COX-2 protein in PIA lesions was present 227. To date, however, 
there are few quantitative analyses of COX-2 expression in relation to Gleason score. In the 
present study, the COX-2 positive rate (40/43, 93%) is higher than in any other report. This 
discrepancy can probably be explained by the fact that there is very heterogeneous expression 
of COX-2 in prostate cancer tissues. A detailed quantitative analysis, based on the information 
from each microscopic field instead of the whole slide of each sample, may be the best way to 
interpret such heterogeneous findings.  
COX-2 expression was induced by focal chronic inflammation, especially T-lymphocytes 
and macrophages infiltration 
Although several reports have shown COX-2 overexpression in PCa, none investigated the 
association between COX-2 expression and the focal inflammation in the PCa areas. It is 
known that inflammation and the related oxidative stress plays a crucial role in inducing 
COX-2 expression in inflammatory lesions 121. Based on our first article, stating that focal 
chronic inflammatory cell infiltration, especially the T-lymphocytes and macrophages, 
inducing the COX-2 expression, we hypothesized that the chronic inflammation in the 
prostate cancer areas may also play a role in COX-2 induction. 
COX-2 IHC staining, focally related to chronic inflammation in tumour areas, has heretofore 
not been noted. Foci of chronic inflammation with accumulation of inflammatory cells were 
detected in all 43 prostate cancer samples using double-labeling of COX-2/CD3 or COX-
2/CD68. Quantification of double labeling showed that T-lymphocytes and macrophages were 
noted more often in the COX-2-positive than in the negative staining tumor areas. A higher T-
lymphocyte density was found in COX-positive than in COX-2-negative fields. Further 
analysis also showed that T-lymphocyte density was related to COX-2 expression in both the 
low and high-Gleason score groups. There was also a significant correlation between T-
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lymphocyte density and COX-2 expression score. Statistical analysis showed significant 
correlation between COX-2 IHC expression score and inflammatory cells density. 
Interestingly, COX-2 expression was significantly related to macrophage density in low but 
not in high Gleason score specimens.  
This observation is in line with our previous finding that COX-2 expression in benign prostate 
epithelium is correlated to local chronic inflammation. The mechanism behind this is not fully 
established. It is now known that most pro-inflammatory mediators stimulate COX-2 
transcription via different types of signalling 198, including: growth factors, such as IGF, 
TGF and EGF 181; nitric oxide (NO) and reactive oxygen species (ROs) 200; and several pro-
inflammatory cytokines such as IL-1 or IFN- 201. COX-2 protein level is also regulated at 
prost-transcriptional level via modulation of the stability of its mRNA. Signals from cytokines 
such as IL-1, TNF- or TLR ligands affect COX-2 mRNA stability. Most of above pro-
inflammatory cytokines are enriched as inflammatory microenvironment component which is 
released by macrophages or activated T-lymphocytes 347. Moreover, in cell co-culture 
experiments, COX-2 is induced by the presence of inflammatory cells 348, and COX-2 protein 
levels are increased in normal prostate cells and prostate cancer cells (PC-3, LNCaP, and 
DU145) after TNF- stimulation in vitro 170, 232. These studies suggest that local inflammation 
could up-regulate COX-2 in adjacent tumour epithelial cells.  
COX-2 up-regulation contributes to the angiogenesis in prostate cancer 
This study provides the first evidence of a direct link between COX-2 and angiogenesis in 
prostate cancer tissue. CD31 is a myeloid progenitor cell antigen found in endothelial cells. 
This biomarker can be found in all types of endothelial cells and has been used to correlate 
angiogenesis in different stages of cancer 188. The spatial relationship between COX-2-
expressing cancer cells and CD31-positive microvessels was investigated using COX-2/CD31 
double IHC staining. COX-2 protein expression was not detected in endothelial cells. CD31-
positive endothelial cells lining microvessels were noted in all prostate cancers specimens. 
Microvessel density (MVD) was significantly increased in high Gleason score cancer, 
compared with those in low Gleason score cancer specimen. MVD was also significantly 
different between COX-2-negative and COX-2-positive stained areas. This finding confirmed 
previous studies in which COX-2 expression was associated with aggressive disease in 
prostate cancer 163, 164, 166-169, and led to the hypothesis that COX-2 drives increased 
neovascularization. The existence and extent of this relationship is essential in the 
determination of therapeutic modalities for the prevention and treatment of prostate cancer. 
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Tumour angiogenesis includes destabilization of pre-existent blood vessels, proliferation of 
vascular endothelial cells, invasion of endothelial cells into the extracellular matrix and, 
finally, the migration and positioning of endothelial cells. Recent evidence suggests a role of 
COX in the process of angiogenesis through the synthesis of angiogenic PGs such as PGE2, 
which induce MMP and VEGF 121, 184-186. Numerous studies have shown co-localization of 
angiogenesis factors, such as VEGF, PDGF, bFGF and TGF-, with COX-2 by 
immunohistochemical staining in different cancer types 187. In some solid tumours such as 
pancreatic cancer, gastric cancer, and endometrial carcinoma, COX-2 was shown to be 
involved in the tumour-associated angiogenesis 349-351. In breast cancer, for instance, the 
density of microvessels was higher in patients with COX-2 expression than in those without 
COX-2 expression 188. Studies of colon cancer cell lines co-cultured with vascular endothelial 
cells demonstrated that COX-2 supports angiogenesis at multiple steps both directly and 
indirectly 189, 190. Through these angiogenesis mediators and their receptors on the endothelial 
cells, COX-2 and PGs increased vascular permeability and induced endothelial cell 
proliferation and migration.  
Clinical trial of COX-2 inhibitor through inhibiting the angiogenesis 
The importance of angiogenesis in tumour metastasis has been well established for over 
30 years 352. In theory, inhibiting angiogenesis might provide a new therapeutic option by 
targeting cancer growth and spread. Several recent articles report a relationship between mean 
MVD and advancing disease in prostate cancer 353, while some reports have negative results 
354, 355. Numerous compounds are examined by the National Cancer Institute (NCI) for their 
potential to prevent or treat cancer. COX-2 inhibitor is currently being tested in both 
prevention and treatment clinical trials. Epidemiological studies have shown that people who 
regularly take NSAIDs, such as aspirin and ibuprofen to treat conditions like arthritis, have 
lower risk of prostate cancer. Celecoxib, a COX-2 inhibitor commonly used to treat arthritis, 
has been shown to inhibit COX-2, and in turn, to reduce the formation, growth, and metastasis 
of several types of experimental cancers. Celecoxib has also been shown to effectively 
decrease tumour angiogenesis and to reduce tumour growth of a variety of experimental 
primary tumours, including colorectal, prostate, and breast cancers 356, 357. 
In summary, the present study raises the possibility that COX-2 may influence tumour 
progression in prostate cancer through mechanisms of the promotion of angiogenesis. The use 
of selective COX-2 inhibitors and angiogenesis inhibitors may play a role in the targeted 
treatment of prostate cancer in the future.  
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Transcription Factor C/EBP Expression in Atrophic Lesions and the Association with 
COX-2 Expression, and Focal Chronic Inflammation (paper III) 
C/EBP expression in prostatic atrophic lesions 
COX-2 is a highly inducible enzyme triggering diverse actions on cell functions, including 
proliferation, migration, and DNA damage. COX-2 transcriptional activation by 
proinflammatory mediators has been extensively characterized. COX-2 could be induced by 
several extracellular signals, including LPS 199; nitric oxide (NO) and reactive oxygen species 
(ROs) 200; pro-inflammatory cytokines 358; and growth factors 181.  Activation of C/EBP and 
in turn phosphorylation of cAMP response element-binding protein (CREB) play a major role 
in the initial stage of COX-2 transcription 359.  
CCAAT/enhancer-binding proteins (C/EBPs) comprise a family of transcription factors with 
at least six members: C/EBP - C/EBP
. These transcription factors are known to be involved 
in the regulation of cell growth and cellular differentiation of several cell types; control of 
metabolism; inflammatory response; and cellular proliferation 208, 214, 215.  
Several cancer models have shown that C/EBP may play a role in neoplastic transformation 
360, 361.  Some studies of human cancers showed increased expression of C/EBP in solid 
tumours related to poor prognosis 360-364. Nevertheless, to the best of our knowledge, there is 
no report dealing with the expression of C/EBP in human prostate, either in malignant or 
benign tissues. To improve the understanding of the role of C/EBP in malignant 
transformation of  prostate, we first investigated its expression in benign prostate tissues, 
especially in the possible cancer precursor PIA 293.  We selected prostatectomy samples of 
BPH patients to perform this study, since it was known that the same morphologic patterns of 
atrophy can be seen in any region of the prostate and in and around nodules of BPH 294. It was 
also known that the overexpression of COX-2 in benign and malignant prostate tissues is 
related to local inflammation 344, 365.  
In this study, we have identified a novel finding of C/EBP expression in benign prostate 
tissues. C/EBP nuclear immunostaining was occasionally observed as focal or scattered 
among epithelial cells of normal-appearing prostate acini. The appearance of C/EBP in these 
epithelial cells was usually near the area of inflammation. Only 5% (± 7%) of normal-
appearing acini showed C/EBP positive staining. In contrast, diffused C/EBP nuclear 
immunostaining was present in PIA lesions: 81% (±19%) of examined PIA had C/EBP
immunostaining.  
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Normally, C/EBP protein is widely expressed in many different tissues, including liver, 
adipose tissue, ovary, and mammary gland. Several studies have shown that C/EBP is a 
critical mediator of steroid hormone-regulated cell proliferation and differentiation.  C/EBPs 
are involved in the regulation, proliferation and differentiation of the cells in mammary gland. 
Moreover, both C/EBP and C/EBP play roles in breast cancer development 212. High 
C/EBP and C/EBP protein levels correlated significantly with expression of cell-cycle 
promoters (cyclin D1 and E) and cell-cycle inhibitory proteins (Rb, p27, p16), but with none 
of the established prognostic parameters. In contrast, C/EBP was statistically related to 
negative estrogen receptor status, high grading, nodal involvement, and high cyclin E and p16 
expression in breast cancer. It was suggested that high C/EBP expression might be involved 
in tumour progression and indicative of an unfavourable prognosis 212. Studies have also 
shown that C/EBP is a critical mediator of steroid hormone-regulated cell proliferation and 
differentiation in the uterine epithelium and stroma 366. A study in mice revealed that C/EBP
is a key mediator of steroid responsiveness in the epithelium and stroma in the mouse uterus 
366. The expression of C/EBP is rapidly induced in the pregnant uterus at the time of 
blastocyst attachment. The expression of C/EBP increases further during the decidualization 
phase of pregnancy. Administration of estrogen or progesterone to ovariectomized females 
induced C/EBP expression in both uterine epithelium and stroma 366.  
In addition, C/EBP appears to play an important role in promoting cells proliferation, and its 
levels are increased in a number of tumours. C/EBP is involved in antioxidant- or 
deoxycholic acid-induced apoptosis of colorectal cancer cells. It has been demonstrated that 
the C/EBP protein is essential for lymphocyte differentiation, and is necessary for the 
antitumour cytotoxicity of murine macrophages. Transfection of C/EBP to murine 
abdominal resident macrophages significantly enhanced their cytotoxicity to tumour cells. 
Overexpression of exogenous C/EBP can induce apoptosis in various malignant cells. 
Moreover, Fas-induced apoptosis in mouse hepatocytes is dependent on C/EBP. 
Nevertheless, until recently, as we know, there have been no reports about the expression of 
C/EBP in human prostate benign or/and malignant tissues. The role of C/EBP in human 
prostate development and disorders is entirely unknown.  
C/EBP expression and its association with local chronic inflammation 
In the present study, C/EBP tended to be present in foci of chronic inflammation.  Double 
IHC staining of C/EBP / CD3 and C/EBP / CD68 confirmed this finding: C/EBP nuclear 
staining in atrophic epithelial cells was predominantly seen adjacent to the T-lymphocytes and 
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macrophages infiltration areas. C/EBP expression was associated with the severity of 
inflammation, both in T-lymphocyte and macrophages inflammation.  
It is known that C/EBP is induced by inflammatory cytokines, such as IL-1, IL-6, and TNF-
 212. The present results suggest that the local inflammatory cells and its related micro-
environment may induce the C/EBP over-expression. This hypothesis was supported by 
additional evidence from the C/EBP expression pattern in normal-appearing acini. C/EBP
positive immunostaining only appeared in a minority (5%) of normal-appearing prostate acini 
and in most cases this was in areas adjacent to chronic inflammation.  
C/EBP expression is related to increased COX-2 expression 
COX-2 expression has been identified as induced by several proinflammatory cytokines, and 
it appeared in various inflammatory lesions and tumours, such as PIA and prostate cancer. In 
this study, we noted that C/EBP expression was closely related to COX-2 expression in 
prostate epithelial cells. Statistical analysis confirmed this observation (p = 0.001). 
Activation of C/EBPs plays a critical role during the initial stage of COX-2 transcription 359. 
COX-2 expression in response to stimulation by proinflammatory mediators is 
transcriptionally regulated through activation of NF-B, C/EBP, AP-1, and CREB-2.  
COX-2 seems to be particularly interesting in PIA, since it was believed to be the potential 
target gene for chemotherapy or chemo-prevention of prostate cancer 367. COX-2 inhibitors 
and NSAIDs have been used in the chemoprevention of several cancers. Several laboratory 
and epidemiological studies suggest that COX-2 inhibitors reduce prostate cancer risk or/and 
have antitumour activities by inhibiting COX-2 enzyme 221, 367-369. The present data show the 
correlation between C/EBP and COX-2 in PIA. It is suggested that C/EBP may also be 
involved in the regulation of COX-2 in prostate epithelial cells, just as in other cells, such as 
fibroblast, macrophage, endothelium, or gastric cancer cells 363, 370, 371. Recent studies have 
made it clear that aspirin and sodium salicylate at therapeutic concentrations selectively 
suppress the expression of COX-2 and inducible nitric oxide synthase (iNOS) induced by LPS 
and IL-1 through inhibiting C/EBP activation in macrophage and fibroblast cells 371, 372. It 
may be further speculated that aspirin or NSAIDs and their in vivo metabolites are capable of 
inhibiting the expression of C/EBP and thereby suppressing COX-2 expression and the 
consequent effects in chemoprevention. Thus, the present study may have clinical 
implications, since it might be suggested that C/EBP could be a target for chemotherapy or 
chemoprevention for prostate cancer.  
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Morphological transition from PIA to HGPIN, and prostate cancer (paper I, II, and IV) 
Morphological analysis is an important way to investigate the link between prostatic focal 
atrophy and prostate malignancies. In 1954, Franks considered a specific subtype of PAH as a 
putative neoplastic precursor, given its close association with PCA 291. Several recent studies 
have re-examined the role of focal atrophy as a potential neoplastic precursor and have 
identified a strong topographic association between atrophy and prostate cancer and/or 
HGPIN 297, 299, 300.  
Recently, a rat prostate model supplied strong evidence that the pathogenesis of prostatic 
neoplasia proceeds from inflammation to PIA and then to HGPIN.  Rats fed 2-Amino-1-
methyl-6-phenylimidazo (4,5-b)pyridine (PhIP) showed significant inflammation and atrophy 
of the prostate and, HGPIN was later observed to develop directly from the atrophic 
epithelium. 
It should be noted that not all the pathologists have noted morphologic transition of PIA, 
HGPIN, and invasive adenocarcinoma 301-305 and that not all HGPIN or small carcinoma 
lesions are associated with atrophy. It is not clear how these parameters are interrelated and 
what intermediates are involved. At the WHO Consensus Conference in Stockholm, it was 
emphasized that no relationship between atrophy and prostate carcinoma or HGPIN has been 
proven 267. Thus, additional studies are required to more fully understand the relation between 
focal atrophic lesions and cancer development in the prostate.  
In the study with 50 radical prostatectomy specimens of prostate adenocarcinoma, we 
identified HGPIN and carcinoma lesions and tried to determine how often they merged with 
PIA.  
Presence of PIA-merging HGPIN 
Among the total of 1,188 HGPIN lesions from all the 50 cases specimens, 17% (198/1,188) 
were detected as merging with PIA. According to the subtypes of prostatic atrophy, the 
majority were simple or mixed atrophy.  One interesting observation was that the distribution 
of PIN patterns in PIA-merging HGPIN lesions was different from the usual histological 
pattern of HGPIN, tufting HGPIN, in most of the slides: flat pattern was the dominant subtype 
PIN in PIA-merging HGPIN lesions. The reason may be that the flat pattern of HGPIN is 
often composed of luminal cells with atypical nuclei in ducts and acini with minor 
architectural changes and is difficult to identify in H&E stained slides even at high 
magnification 373, however, it is easy to recognize by means of the CK5 or GSTP1 
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immunostaining. Another possible interpretation may be that in the PIA-merging HGPIN, the 
flat subtype is probably the earliest type of HGPIN, since it had somewhat similar architecture 
as in SA, except for the prominent nucleoli and the absence of CK5 and GSTP1. 
CK5 and GSTP1 immunostaining as possible markers for atrophic epithelium 
At the beginning of this study, four antibodies, CK5, GSTP1, c-MET, and C/EBP, were 
tested for selecting possible markers in detecting the atrophic epithelium. The results showed 
that both CK5 and GSTP1 could be used as markers for the atrophic epithelium, where it is 
difficult to distinguish it from other components on the routine H&E stained slides.  
Although a few reports have confirmed the development of PIA to HGPIN 268, 293, 300, there are 
also numerous contradictory reports 301, 303. How to recognize the atrophic fraction in such 
lesions is a crucial question, since it is difficult to detect a tiny atrophic fraction in HGPIN 
lesions in the ordinary H&E stained slides. The present study showed that by means of CK5 
and GSTP1 IHC immunostaining, it was easier to detect the atrophic epithelial cells in PIA-
merging HGPIN or PIA-merging PCa lesions, especially in a lesion that has made the 
transition into malignancy. CK5, a basal cell marker, appeared in the luminal cells of PIA 306, 
374, and was absent in both HGPIN and prostate cancer. GSTP1 protein was normally 
expressed in basal epithelium and was absent in most luminal epithelial cells. In PIA lesions, 
strong anti-GSTP1 staining was seen in most of the atrophic epithelial cells. Absence of 
GSTP1 expression is common in HGPIN lesions and prostate cancer cells. These results 
suggest that both CK5 and GSTP1 are suitable markers for detecting and recognizing the 
atrophic epithelial cells in various lesions.   
Presence of PIA-merging PCa 
In morphological studies, atrophic lesions have been noted near early carcinoma lesions 299, 
and, at times, to have merged with adenocarcinoma 300, 375. The present work adds evidence 
that there is a direct transition from PIA to prostate carcinoma. Fourteen (28%) of the samples 
were found to have small foci of PIA-merging PCa. By means of CK5 or GSTP1 
immunostaining, it was easy to recognize the atrophic epithelial cells in these lesions. The 
contrast image of GSTP1 in the atrophic epithelium and prostate cancer cells demonstrates the 
GSPT1 hypermethylation in malignant cells. This finding supports the hypothesis that some 
prostate atrophy lesions may directly give rise to carcinoma, as has previously been suggested 
291, 300, 376.  
Cluster of atypical epithelial proliferation
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One striking finding in this study is that clusters of atypical epithelial proliferation were found 
in some PIA lesions, where a focal dominant chronic inflammation exists. These cluster cells 
appeared to grow in a budding pattern in the luminal layer. Cells were variable in size and 
shape, showed eosinophilic or basophilic cytoplasm, had enlarged nuclear with 
hyperchromasia, and contained severe nuclear atypia with frequent prominent nucleoli. The 
latter fulfil the criteria for the diagnosis of HGPIN. Architecturally, such lesions maintain a 
normal-appearing or atrophic architecture and a continuous basal cell layer. These lesions 
were usually surrounded by various degrees of chronic inflammation. Like the epithelium in 
other PIA lesions, such clusters of atypical epithelia also showed increased immunostaining 
for CK5 and GSTP1, from weak to moderate immunostaining intensity. Since there were no 
previous data concerning this, we examined these lesions to determine how frequently it 
appeared. Five cases with 16 clusters of atypical epithelia proliferation lesions were found 
from 50 prostatectomy specimens. 
Such focal atypical epithelial cells, although they were few in isolated PIA lesions, have 
fulfiled the criteria for HGPIN after routine light microscopic examination. We thereby 
postulated that a HGPIN lesion might develop from these clusters of atypical epithelial cells, 
meaning that some PIA lesion may develop directly into HGPIN. It is suggested that these 
cluster of cells may be a consequence of regenerative proliferation after the activation of 
“stem cells” or their progeny, the intermediate cells, by chronic stress.  
In summary, morphological transition from PIA to HGPIN and carcinoma were occasionally 
found in 50 prostatectomy specimens. CK5 and GSTP1 are useful markers for detecting and 
recognizing the atrophic epithelial cells in these lesions. Considering the findings in this study, 
we hypothesize that the transition from PIA to HGPIN and prostate cancer may go through 
pathways with and without an intermediate morphological stage of low grade PIN.  
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CONCLUSIONS 
The results from the studies included in the current thesis show that: 
 COX-2 is overexpressed in prostate PIA lesions. 
 The epithelium of these COX-2 positive immunostained glands has high proliferation 
index and increased Bcl-2 protein level. 
 Transcription factor C/EBP is expressed in PIA lesions and is correlated to COX-2. 
 The COX-2 expression was positively associated to Gleason score and the 
angiogenesis in prostate cancer. 
 Focal chronic inflammation, predominantly T-lymphocytes and macrophages infiltration, 
plays an important role in inducing COX-2 expression both in benign and malignant 
prostate tissues. 
 Morphological analysis supported the hypothesis that PIA could develop into HGPIN 
and/or prostate cancer directly or indirectly. 
Fig 5. Cellular and molecular model of transition from PIA to HGPIN and prostate cancer.  
L, luminal epithelium; B, basal epithelium; M, macrophage; T, T-lymphocyte; PIA, proliferative 
inflammatory atrophy; LGPIN, low grade prostatic intraepithelium neoplasia; HGPIN, high grade 
prostatic intraepithelial neoplasia; PCa, prostate cancer. b-c, transition from PIA to HGPIN; b-d, 
transition from PIA to PCa.  
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